CL2014003355A1 - Compuestos tricíclicos sustituidos, inhibidores del receptor del factor de crecimiento de fibroblastos (fgfr); composicion farmaceutica que los comprende; metodo para tratar cancer, trastorno mieloproliferativo, trastorno esqueletico, trastorno de hipofosfatemia, entre otros. - Google Patents

Compuestos tricíclicos sustituidos, inhibidores del receptor del factor de crecimiento de fibroblastos (fgfr); composicion farmaceutica que los comprende; metodo para tratar cancer, trastorno mieloproliferativo, trastorno esqueletico, trastorno de hipofosfatemia, entre otros.

Info

Publication number: CL2014003355A1
Authority: CL; Chile
Prior art keywords: disorder; fgfr; inhibitors; pharmaceutical composition; growth factor
Prior art date: 2012-06-13

Application number

CL2014003355A

Other languages

English (en)

Inventor

Wenqing Yao

Chunhong He

Liangxing Wu

Colin Zhang

Yaping Sun

Liang Lu

Ding-Quan Qian

Meizhong Xu

Jincong Zhuo

Original Assignee

Incyte Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-06-13

Filing date

2014-12-10

Publication date

2015-06-12

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49486650&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014003355(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-12-10 Application filed by Incyte Corp filed Critical Incyte Corp

2015-06-12 Publication of CL2014003355A1 publication Critical patent/CL2014003355A1/es

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Orthopedic Medicine & Surgery (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Pyridine Compounds (AREA)

CL2014003355A 2012-06-13 2014-12-10 Compuestos tricíclicos sustituidos, inhibidores del receptor del factor de crecimiento de fibroblastos (fgfr); composicion farmaceutica que los comprende; metodo para tratar cancer, trastorno mieloproliferativo, trastorno esqueletico, trastorno de hipofosfatemia, entre otros. CL2014003355A1 (es)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date
US201261659245P	2012-06-13	2012-06-13
US201261691463P	2012-08-21	2012-08-21
US201261740012P	2012-12-20	2012-12-20
US201361774841P	2013-03-08	2013-03-08

Publications (1)

Publication Number	Publication Date
CL2014003355A1 true CL2014003355A1 (es)	2015-06-12

Family

ID=49486650

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
CL2014003355A CL2014003355A1 (es)	2012-06-13	2014-12-10	Compuestos tricíclicos sustituidos, inhibidores del receptor del factor de crecimiento de fibroblastos (fgfr); composicion farmaceutica que los comprende; metodo para tratar cancer, trastorno mieloproliferativo, trastorno esqueletico, trastorno de hipofosfatemia, entre otros.
CL2017001984A CL2017001984A1 (es)	2012-06-13	2017-08-03	Compuestos tricíclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroblastos (fgfr).(solicitud divisional 3355-2014)

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
CL2017001984A CL2017001984A1 (es)	2012-06-13	2017-08-03	Compuestos tricíclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroblastos (fgfr).(solicitud divisional 3355-2014)

Country Status (38)

Country	Link
US (6)	US9611267B2 (es)
EP (5)	EP3495367B1 (es)
JP (8)	JP6301321B2 (es)
KR (3)	KR102140426B1 (es)
CN (3)	CN104507943B (es)
AR (1)	AR091424A1 (es)
AU (5)	AU2013287176C1 (es)
BR (1)	BR112014030812B1 (es)
CA (2)	CA2876689C (es)
CL (2)	CL2014003355A1 (es)
CO (1)	CO7240375A2 (es)
CY (4)	CY1118744T1 (es)
DK (3)	DK3495367T3 (es)
EA (1)	EA036592B1 (es)
EC (1)	ECSP22091792A (es)
ES (4)	ES2832497T3 (es)
HR (3)	HRP20170430T1 (es)
HU (4)	HUE042374T2 (es)
IL (5)	IL289834B2 (es)
LT (4)	LT3495367T (es)
LU (1)	LUC00222I2 (es)
ME (2)	ME03300B (es)
MX (3)	MX359293B (es)
MY (2)	MY171375A (es)
NL (1)	NL301131I2 (es)
NO (1)	NO2021034I1 (es)
NZ (3)	NZ743274A (es)
PE (2)	PE20190736A1 (es)
PH (2)	PH12019502809B1 (es)
PL (3)	PL3176170T3 (es)
PT (3)	PT3176170T (es)
RS (3)	RS61089B1 (es)
SG (2)	SG10201610416TA (es)
SI (3)	SI3176170T1 (es)
SM (3)	SMT201700146T1 (es)
TW (3)	TWI769529B (es)
UA (2)	UA125503C2 (es)
WO (1)	WO2014007951A2 (es)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US10632126B2 (en)	2015-02-20	2020-04-28	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
US10738048B2 (en)	2015-02-20	2020-08-11	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
US10813930B2 (en)	2010-12-22	2020-10-27	Incyte Corporation	Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
US10851105B2 (en)	2014-10-22	2020-12-01	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
US10947230B2 (en)	2013-04-19	2021-03-16	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
US11053246B2 (en)	2012-06-13	2021-07-06	Incyte Corporation	Substituted tricyclic compounds as FGFR inhibitors
US11174257B2 (en)	2018-05-04	2021-11-16	Incyte Corporation	Salts of an FGFR inhibitor
US11407750B2 (en)	2019-12-04	2022-08-09	Incyte Corporation	Derivatives of an FGFR inhibitor
US11466004B2 (en)	2018-05-04	2022-10-11	Incyte Corporation	Solid forms of an FGFR inhibitor and processes for preparing the same
US11472801B2 (en)	2017-05-26	2022-10-18	Incyte Corporation	Crystalline forms of a FGFR inhibitor and processes for preparing the same
US11566028B2 (en)	2019-10-16	2023-01-31	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
US11591329B2 (en)	2019-07-09	2023-02-28	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
US11607416B2 (en)	2019-10-14	2023-03-21	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
US11628162B2 (en)	2019-03-08	2023-04-18	Incyte Corporation	Methods of treating cancer with an FGFR inhibitor
US11897891B2 (en)	2019-12-04	2024-02-13	Incyte Corporation	Tricyclic heterocycles as FGFR inhibitors
US11939331B2 (en)	2021-06-09	2024-03-26	Incyte Corporation	Tricyclic heterocycles as FGFR inhibitors
US12012409B2 (en)	2020-01-15	2024-06-18	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
US12065494B2 (en)	2021-04-12	2024-08-20	Incyte Corporation	Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent
US12122767B2 (en)	2019-10-01	2024-10-22	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI2861566T1 (sl)	2012-06-13	2017-03-31	F. Hoffmann-La Roche Ag	Novi diazaspirocikloalkan in azaspirocikloalkan
US9388185B2 (en)	2012-08-10	2016-07-12	Incyte Holdings Corporation	Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
RS59512B1 (sr)	2012-09-25	2019-12-31	Hoffmann La Roche	Derivati heksahidropirolo[3,4−c]pirola i srodna jedinjenja kao inhibitori autotaksina (atx) i kao inhibitori proizvodnje lizofosfatidne kiseline (lpa) za lečenje npr. bubrežnih bolesti
US9266892B2 (en)	2012-12-19	2016-02-23	Incyte Holdings Corporation	Fused pyrazoles as FGFR inhibitors
AR094812A1 (es)	2013-02-20	2015-08-26	Eisai R&D Man Co Ltd	Derivado de piridina monocíclico como inhibidor del fgfr
AR095079A1 (es)	2013-03-12	2015-09-16	Hoffmann La Roche	Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
US9783504B2 (en) *	2013-07-09	2017-10-10	Dana-Farber Cancer Institute, Inc.	Kinase inhibitors for the treatment of disease
EA201691044A1 (ru)	2013-11-26	2016-09-30	Ф. Хоффманн-Ля Рош Аг	Новый октагидро-циклобута[1,2-c;3,4-c']дипиррол-2-ил
SMT201900680T1 (it) *	2014-02-13	2020-01-14	Incyte Corp	Ciclopropilammine come inibitori di lsd1
CN106029667B (zh)	2014-03-26	2019-08-23	豪夫迈·罗氏有限公司	作为自分泌运动因子(atx)和溶血磷脂酸(lpa)生产抑制剂的稠合[1,4]二氮杂*化合物
MX370659B (es)	2014-03-26	2019-12-19	Hoffmann La Roche	Compuestos bicíclicos como inhibidores de producción de autotaxina (atx) y ácido lisofosfatídico (lpa).
SI3179992T1 (sl)	2014-08-11	2022-09-30	Acerta Pharma B.V.	Terapevtske kombinacije zaviralca BTK, zaviralca PD-1 in/ali zaviralca PD-L1
HUE056329T2 (hu)	2014-08-11	2022-02-28	Acerta Pharma Bv	BTK-inhibitor és BCL-2-inhibitor terápiás kombinációi
TW201618773A (zh)	2014-08-11	2016-06-01	艾森塔製藥公司	Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑、及／或ｃｄｋ４／６抑制劑的治療組合物
AU2015304465B2 (en)	2014-08-18	2019-05-09	Eisai R&D Management Co., Ltd.	Salt of monocyclic pyridine derivative and crystal thereof
US9255096B1 (en)	2014-10-07	2016-02-09	Allergan, Inc.	Substituted 1,2,3,4-tetrahydrobenzo[C][2,7] naphthyridines and derivatives thereof as kinase inhibitors
US20160115164A1 (en) *	2014-10-22	2016-04-28	Incyte Corporation	Bicyclic heterocycles as fgfr4 inhibitors
US9694084B2 (en)	2014-12-23	2017-07-04	Dana-Farber Cancer Institute, Inc.	Methods to induce targeted protein degradation through bifunctional molecules
US9580423B2 (en)	2015-02-20	2017-02-28	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
MA41898A (fr)	2015-04-10	2018-02-13	Hoffmann La Roche	Dérivés de quinazolinone bicyclique
PE20180479A1 (es)	2015-09-04	2018-03-07	Hoffmann La Roche	Nuevos derivados de fenoximetilo
PE20180552A1 (es)	2015-09-24	2018-04-02	Hoffmann La Roche	Nuevos compuestos biciclicos como inhibidores duales de atx/ca
MA42919A (fr)	2015-09-24	2018-08-01	Hoffmann La Roche	Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
EP3353181B1 (en)	2015-09-24	2021-08-11	F. Hoffmann-La Roche AG	Bicyclic compounds as dual atx/ca inhibitors
RU2018114289A (ru)	2015-09-24	2019-10-24	Ф. Хоффманн-Ля Рош Аг	Бициклические соединения в качестве ингибиторов аутотаксина (atx)
CN107459519A (zh)	2016-06-06	2017-12-12	上海艾力斯医药科技有限公司	稠合嘧啶哌啶环衍生物及其制备方法和应用
EP3596060B1 (en)	2017-03-16	2023-09-20	F. Hoffmann-La Roche AG	New bicyclic compounds as atx inhibitors
SG11201908560SA (en)	2017-03-16	2019-10-30	Hoffmann La Roche	Heterocyclic compounds useful as dual atx/ca inhibitors
US11760934B2 (en)	2017-11-17	2023-09-19	Dic Corporation	Polymerizable compound, and liquid crystal composition and liquid crystal display element in which the compound is used
WO2019167640A1 (ja)	2018-03-01	2019-09-06	Dic株式会社	重合性化合物並びにそれを使用した液晶組成物及び液晶表示素子
JPWO2019189241A1 (ja)	2018-03-28	2021-03-18	エーザイ・アール・アンド・ディー・マネジメント株式会社	肝細胞癌治療剤
CN110386932A (zh) *	2018-04-20	2019-10-29	艾科思莱德制药公司	用于抗肿瘤疗法中的双重atm和dna-pk抑制剂
EP3829543A1 (en)	2018-07-31	2021-06-09	Loxo Oncology, Inc.	Spray-dried dispersions and formulations of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoro propan-2-yl)-1h-pyrazole-4-carboxamide
WO2020081689A1 (en) *	2018-10-16	2020-04-23	Dana-Farber Cancer Institute, Inc.	Azaindole inhibitors of wild-type and mutant forms of lrrk2
EP3898626A1 (en)	2018-12-19	2021-10-27	Array Biopharma, Inc.	Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
CN113474337A (zh)	2018-12-19	2021-10-01	奥瑞生物药品公司	作为fgfr抑制剂用于治疗癌症的7-((3，5-二甲氧基苯基)氨基)喹喔啉衍生物
MX2021009863A (es)	2019-03-21	2021-11-12	Onxeo	Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer.
CN109939110A (zh) *	2019-05-08	2019-06-28	湖南中医药大学	药根碱在制备抗血栓药物中的应用
JP7121218B1 (ja)	2019-08-08	2022-08-17	▲ザン▼州片仔▲ファン▼薬業股▲フン▼有限公司	ピラジン－２（１ｈ）－オン系化合物の製造方法
WO2021023192A1 (zh) *	2019-08-08	2021-02-11	漳州片仔癀药业股份有限公司	吡嗪-2(1h)-酮类化合物的a晶型和b晶型及其制备方法
MX2022001952A (es) *	2019-08-15	2022-06-02	Black Diamond Therapeutics Inc	Compuestos de alquinil quinazolina.
CN114761006A (zh)	2019-11-08	2022-07-15	Inserm(法国国家健康医学研究院)	对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021148581A1 (en)	2020-01-22	2021-07-29	Onxeo	Novel dbait molecule and its use
JP2023533724A (ja)	2020-07-02	2023-08-04	インサイト・コーポレイション	Ｊａｋ２ｖ６１７ｆ阻害剤としての三環式尿素化合物
WO2022193227A1 (en) *	2021-03-18	2022-09-22	Nutshell Biotech (Shanghai) Co., Ltd.	Fused ring compounds as inhibitors of fgfr tyrosine kinases
US20230226040A1 (en)	2021-11-22	2023-07-20	Incyte Corporation	Combination therapy comprising an fgfr inhibitor and a kras inhibitor
WO2023195018A1 (en) *	2022-04-05	2023-10-12	Msn Laboratories Private Limited, R&D Center	Solid dispersions of 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2h-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one
WO2024206858A1 (en)	2023-03-30	2024-10-03	Revolution Medicines, Inc.	Compositions for inducing ras gtp hydrolysis and uses thereof
TW202508595A (zh)	2023-05-04	2025-03-01	美商銳新醫藥公司	用於ｒａｓ相關疾病或病症之組合療法
US11884667B1 (en)	2023-07-13	2024-01-30	King Faisal University	Substituted pyrrolo[2,3-c][2,7]naphthyridines as CK2 inhibitors
WO2025034702A1 (en)	2023-08-07	2025-02-13	Revolution Medicines, Inc.	Rmc-6291 for use in the treatment of ras protein-related disease or disorder
US11897883B1 (en)	2023-09-01	2024-02-13	King Faisal University	Pyrrolo[3,2-c][1,6]naphthyridine-2-carboxylic acid compounds as CK2 inhibitors
US11891377B1 (en)	2023-09-06	2024-02-06	King Faisal University	Pyrrolo[3,2-c][2,7]naphthyridine-2-carboxylic acid compounds as CK2 inhibitors
US11866437B1 (en)	2023-09-15	2024-01-09	King Faisal University	1,2-dioxo-2,3-dihydro-1H-pyrrolo[2,3-c]quinoline-7-carboxylic acid compounds as CK2 inhibitors
US20250154171A1 (en)	2023-10-12	2025-05-15	Revolution Medicines, Inc.	Ras inhibitors

Family Cites Families (813)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE280853C (es)
US850370A (en)	1906-06-05	1907-04-16	William L Hynes	Water-automobile.
DE2156720A1 (de)	1971-11-16	1973-05-24	Bayer Ag	Pyrimido eckige klammer auf 4,5-d eckige klammer zu pyrimidine
US3984021A (en)	1972-09-11	1976-10-05	Uhlig Gerhardt E	Safety closure container
US3894021A (en)	1974-01-28	1975-07-08	Squibb & Sons Inc	Derivatives of 1,7-dihydro-2H-pyrazolo{8 4{40 ,3{40 :5,6{9 pyrido{8 4,3-D{9 pyrimidine-2,4-(3H)-diones
JPS5120580B2 (es)	1974-06-19	1976-06-25
US4347348A (en)	1978-06-05	1982-08-31	Chernikhov Alexei Y	Heat-resistant heterocyclic polymers and methods for producing same
FR2428654A1 (fr)	1978-06-13	1980-01-11	Chernikhov Alexei	Polymeres heterocycliques thermostables et leurs procedes de preparation
CH641470A5 (de)	1978-08-30	1984-02-29	Ciba Geigy Ag	Imidgruppen enthaltende silane.
CH635828A5 (de)	1978-08-30	1983-04-29	Ciba Geigy Ag	N-substituierte imide und bisimide.
US4339267A (en)	1980-01-18	1982-07-13	E. I. Du Pont De Nemours And Company	Herbicidal sulfonamides
US4405520A (en)	1980-10-22	1983-09-20	Plastics Engineering Company	Addition products of di-acetylene-terminated polymide derivatives and dienophiles having terminal maleimide grops
US4405786A (en)	1980-10-22	1983-09-20	Plastics Engineering Company	Addition products of di-acetylene-terminated polyimide derivatives and an dienophile having ethylene groups
US4405519A (en)	1980-10-22	1983-09-20	Plastics Engineering Company	Di-Acetylene-terminated polyimide derivatives
US4402878A (en)	1980-10-22	1983-09-06	Plastics Engineering Company	Addition products of di-acetylene-terminated polyimide derivatives with a polyimide having terminal non-conjugated acetylene groups
US4460773A (en)	1982-02-05	1984-07-17	Lion Corporation	1-Phenyl-1H-pyrazolo [3,4-b]pyrazine derivatives and process for preparing same
DE3432983A1 (de)	1983-09-07	1985-04-18	Lion Corp., Tokio/Tokyo	1,5-disubstituierte 1h-pyrazolo(3,4-b)-pyrazin-derivate und antitumormittel, die diese enthalten
JPS62273979A (ja)	1986-05-21	1987-11-28	Lion Corp	１，５−置換−１Ｈ−ピラゾロ〔３，４−ｂ〕ピラジン誘導体及び該化合物を含有する抗腫瘍剤
JPS6310630A (ja)	1986-06-23	1988-01-18	Teijin Ltd	芳香族ポリアミドイミドエ−テルの製造法
JPS6317882A (ja)	1986-07-09	1988-01-25	Lion Corp	５−置換−１Ｈ−ピラゾロ〔３，４−ｂ〕ピラジン誘導体及び該化合物を含有する抗腫瘍剤
US4859672A (en)	1986-10-29	1989-08-22	Rorer Pharmaceutical Corporation	Pyrido[2,3-d]pyrimidinone and imidazo[4,5-b]pyrimidinone
US4874803A (en)	1987-09-21	1989-10-17	Pennwalt Corporation	Dianhydride coupled polymer stabilizers
DE3814549A1 (de)	1987-10-30	1989-05-18	Bayer Ag	N-substituierte derivate von 1-desoxynojirimycin und 1-desoxymannonojirimycin, verfahren zu deren herstellung und deren verwendung in arzneimitteln
JPH029895A (ja)	1988-06-28	1990-01-12	Lion Corp	ヌクレオシド類似化合物及び抗腫瘍剤
DD280853A1 (de)	1989-03-21	1990-07-18	Akad Nauk Sssr	Bindemittel fuer elektroden, vorzugsweise fuer polymerelektroden
US5159054A (en)	1989-05-16	1992-10-27	The United States Of America As Represented By The Secretary Of The Navy	Synthesis of phthalonitrile resins containing ether and imide linkages
JP2845957B2 (ja)	1989-07-17	1999-01-13	三井化学株式会社	イミド環を有する新規ジフェノール類およびその製造方法
US5726302A (en)	1989-09-15	1998-03-10	Gensia Inc.	Water soluble adenosine kinase inhibitors
DE3937633A1 (de)	1989-11-11	1991-05-16	Bayer Ag	Heterocyclische verbindungen und deren verwendung als pigmente und farbstoffe
WO1991010172A1 (de)	1989-12-28	1991-07-11	Hoechst Aktiengesellschaft	Biskationische säureamid- und -imidderivate als ladungssteuermittel
US5329046A (en)	1989-12-28	1994-07-12	Hoechst Aktiengesellschaft	Biscationic acid amide and imide derivatives and processes for their preparation
JP2883670B2 (ja)	1990-03-23	1999-04-19	三井化学株式会社	イミド環を有する新規ビスフェノール類およびその製造方法
GB9113137D0 (en)	1990-07-13	1991-08-07	Ici Plc	Thioxo heterocycles
WO1992006078A1 (en)	1990-10-03	1992-04-16	Commonwealth Scientific And Industrial Research Organisation	Epoxy resins based on diaminobisimide compounds
JPH04158084A (ja)	1990-10-22	1992-06-01	Fuji Photo Film Co Ltd	記録材料
JPH04179576A (ja)	1990-11-14	1992-06-26	Fuji Photo Film Co Ltd	記録材料
JPH04328121A (ja)	1991-04-26	1992-11-17	Sumitomo Bakelite Co Ltd	半導体封止用エポキシ樹脂組成物
AU657986B2 (en)	1991-06-14	1995-03-30	Pharmacia & Upjohn Company	Imidazo(1,5-a)quinoxalines
DE4119767A1 (de)	1991-06-15	1992-12-17	Dresden Arzneimittel	Verfahren zur herstellung von (pyrimid-2-yl-thio- bzw. seleno)-essigsaeurederivaten
US5521184A (en)	1992-04-03	1996-05-28	Ciba-Geigy Corporation	Pyrimidine derivatives and processes for the preparation thereof
JP3279635B2 (ja)	1992-05-18	2002-04-30	鐘淵化学工業株式会社	ヒドロシリル基含有イミド化合物
JP3232123B2 (ja)	1992-05-20	2001-11-26	鐘淵化学工業株式会社	硬化性組成物
JPH07506836A (ja)	1992-05-28	1995-07-27	コモンウェルス・サイエンティフィック・アンド・インダストリアル・リサーチ・オーガニゼイション	ビスマレイミド化合物
JPH08504196A (ja)	1992-12-07	1996-05-07	コモンウェルス・サイエンティフィック・アンド・インダストリアル・リサーチ・オーガニゼイション	ビスナドイミド
CA2153595A1 (en)	1993-01-11	1994-07-21	Anthony F. Garito	Polycyclic aromatic compounds having nonlinear optical properties
AU4293193A (en)	1993-04-28	1994-11-21	Du Pont Merck Pharmaceutical Company, The	Novel trisubstituted aromatic amines useful for the treatment of cognitive deficits
US5536725A (en)	1993-08-25	1996-07-16	Fmc Corporation	Insecticidal substituted-2,4-diamino-5,6,7,8-tetrahydroquinazolines
PT731795E (pt)	1993-11-30	2000-05-31	Searle & Co	Pirazolilbenzenossulfonamidas para o tratamento de inflamacoes
AU8074894A (en)	1994-02-02	1995-08-21	Eli Lilly And Company	Hiv protease inhibitors and intermediates
US5480887A (en)	1994-02-02	1996-01-02	Eli Lilly And Company	Protease inhibitors
TJ342B (en)	1994-11-14	2002-10-06	Warner Lambert Co	Derivatives of 6-aryl pyrido Ä2,3-dÜ pyrimidines and naphthyridines pharmaceutical composition possess inhibiting effect of cellular proliferation pr ovoking protein tyrosine kinase and method of inhibiting cellular proliferation
US7125880B1 (en)	1995-06-06	2006-10-24	Pfizer Inc.	Corticotropin releasing factor antagonists
US5783577A (en)	1995-09-15	1998-07-21	Trega Biosciences, Inc.	Synthesis of quinazolinone libraries and derivatives thereof
JPH09188812A (ja)	1996-01-11	1997-07-22	Mitsui Toatsu Chem Inc	結晶化促進剤
JP3531169B2 (ja)	1996-06-11	2004-05-24	三菱ウェルファーマ株式会社	縮合ヘテロ環化合物およびその医薬用途
CZ292806B6 (cs)	1996-08-06	2003-12-17	Pfizer Inc.	Pyrido- nebo pyrimido-6,6- nebo -6,7-bicyklické deriváty, farmaceutické kompozice na jejich bázi
AU4054197A (en)	1996-08-14	1998-03-06	Warner-Lambert Company	2-phenyl benzimidazole derivatives as mcp-1 antagonists
JP3669783B2 (ja)	1996-08-21	2005-07-13	三井化学株式会社	有機電界発光素子
US5994364A (en)	1996-09-13	1999-11-30	Schering Corporation	Tricyclic antitumor farnesyl protein transferase inhibitors
AU6908398A (en)	1996-10-28	1998-05-22	Versicor Inc	Fused 2,4-pyrimidinedione combinatorial libraries and biologically active fused 2,4-pyramidinediones
EP0946523A1 (en)	1996-12-23	1999-10-06	Celltech Therapeutics Limited	Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
JP2001509805A (ja)	1997-02-05	2001-07-24	ワーナー−ランバート・コンパニー	細胞増殖阻害剤としてのピリド〔２，３−ｄ〕ピリミジンおよび４−アミノピリミジン
EP0973777A1 (en)	1997-04-11	2000-01-26	Abbott Laboratories	Furopyridine, thienopyridine, pyrrolopyridine and related pyrimidine, pyridazine and triazine compounds useful in controlling chemical synaptic transmission
EP1001946B1 (en)	1997-05-28	2010-12-29	Aventis Pharmaceuticals Inc.	QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR p56lck TYROSINE KINASES
GB9716231D0 (en)	1997-07-31	1997-10-08	Amersham Int Ltd	Base analogues
EP0994892A1 (en)	1997-08-11	2000-04-26	Cor Therapeutics, Inc.	SELECTIVE FACTOR Xa INHIBITORS
KR20010023089A (ko)	1997-08-20	2001-03-26	로즈 암스트롱, 크리스틴 에이. 트러트웨인	단백질 티로신 키나제 및 세포주기 키나제 매개의 세포증식 억제용 나프티리디논
US6465484B1 (en)	1997-09-26	2002-10-15	Merck & Co., Inc.	Angiogenesis inhibitors
JPH11171865A (ja)	1997-12-04	1999-06-29	Yoshitomi Pharmaceut Ind Ltd	縮合ヘテロ環化合物
US6350749B1 (en)	1998-02-20	2002-02-26	Takeda Chemical Industries, Ltd.	Aminoguanidine hydrazone derivatives, process for producing the same and drugs thereof
AU9298798A (en)	1998-05-15	1999-12-06	Guilford Pharmaceuticals Inc.	Fused tricyclic compounds which inhibit parp activity
NZ508268A (en)	1998-05-26	2004-02-27	Warner Lambert Co	Bicyclic pyrimidines and bicyclic 3,4- dihydropyrimidines as inhibitors of cellular proliferation
US20040044012A1 (en)	1998-05-26	2004-03-04	Dobrusin Ellen Myra	Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
EP1086085A1 (en)	1998-06-12	2001-03-28	Vertex Pharmaceuticals Incorporated	INHIBITORS OF p38
AU5620299A (en)	1998-08-11	2000-03-06	Novartis Ag	Isoquinoline derivatives with angiogenesis inhibiting activity
JP2000123973A (ja)	1998-10-09	2000-04-28	Canon Inc	有機発光素子
CA2347474C (en)	1998-10-23	2008-08-26	F. Hoffmann-La Roche Ag	Bicyclic nitrogen heterocycles
GB9823103D0 (en)	1998-10-23	1998-12-16	Pfizer Ltd	Pharmaceutically active compounds
US6133031A (en)	1999-08-19	2000-10-17	Isis Pharmaceuticals Inc.	Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en)	1999-03-06	1999-04-28	Zeneca Ltd	Chemical compounds
DE19912638A1 (de)	1999-03-20	2000-09-21	Bayer Ag	Naphthylcarbonsäureamid-substituierte Sulfonamide
DE19920790A1 (de)	1999-05-06	2000-11-09	Bayer Ag	Bis-Sulfonamide mit anti-HCMV-Wirkung
PE20010306A1 (es)	1999-07-02	2001-03-29	Agouron Pharma	Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
JP4041624B2 (ja)	1999-07-21	2008-01-30	三井化学株式会社	有機電界発光素子
HU228449B1 (en)	1999-09-24	2013-03-28	Janssen Pharmaceutica Nv	Antiviral compositions
DE19946289A1 (de)	1999-09-28	2001-03-29	Basf Ag	Benzodiazepin-Derivate, deren Herstellung und Anwendung
JP3961830B2 (ja)	1999-10-21	2007-08-22	エフ．ホフマン−ラロシュアーゲー	ｐ３８プロテインキナーゼのインヒビターとしてのヘテロアルキルアミノ置換二環式窒素複素環
CA2388140C (en)	1999-10-21	2008-09-02	F. Hoffmann-La Roche Ag	Alkylamino substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase
TWI271406B (en)	1999-12-13	2007-01-21	Eisai Co Ltd	Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same
DE60033316T2 (de)	1999-12-29	2007-11-22	Wyeth	Tricyclische proteinkinasehemmer
ATE398110T1 (de)	2000-01-24	2008-07-15	Warner Lambert Co	3-aminochinazolin-2,4-dione als antibakterielle mittel
EP1255755A1 (en)	2000-01-27	2002-11-13	Warner-Lambert Company	Pyridopyrimidinone derivatives for treatment of neurodegenerative disease
EP1257551B1 (de)	2000-02-01	2007-09-05	Abbott GmbH & Co. KG	Heterozyklische verbindungen und deren anwendung als parp-inhibitoren
DK1257550T3 (da)	2000-02-04	2006-03-27	Portola Pharm Inc	Blodplade-ADP-receptor-inhibitor
PT1254138E (pt)	2000-02-09	2005-09-30	Novartis Ag	Derivados de piridina que inibem a angiogenese e/ou o receptor de tirosina cinase do vegf
GB0004890D0 (en)	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
EP1272185B1 (en)	2000-03-06	2005-07-27	AstraZeneca AB	Use of quinazoline derivatives as angiogenesis inhibitors
JP2001265031A (ja)	2000-03-15	2001-09-28	Fuji Xerox Co Ltd	電子写真感光体、プロセスカートリッジ、及び、電子写真装置
DE10012549A1 (de)	2000-03-15	2001-09-20	Bayer Ag	Arzneimittel gegen virale Erkrankungen
CN1249051C (zh)	2000-04-28	2006-04-05	阿卡蒂亚药品公司	毒蕈碱性激动剂
EP1278744A1 (en)	2000-05-05	2003-01-29	Millenium Pharmaceuticals, Inc.	Heterobicyclic sulfonamides and their use as platelet adp receptor inhibitors
JP2004501918A (ja)	2000-06-23	2004-01-22	ブリストル−マイヤーズ　スクイブ　ファーマ　カンパニー	Ｘａ因子阻害剤としての１−（ヘテロアリール−フェニル）−縮合ピラゾール誘導体
SI1294358T1 (en)	2000-06-28	2004-12-31	Smithkline Beecham Plc	Wet milling process
US20050009876A1 (en)	2000-07-31	2005-01-13	Bhagwat Shripad S.	Indazole compounds, compositions thereof and methods of treatment therewith
WO2002012442A2 (en)	2000-08-07	2002-02-14	Neurogen Corporation	Heterocyclic compounds as ligands of the gabaa receptor
DK1309593T3 (da)	2000-08-14	2006-07-17	Ortho Mcneil Pharm Inc	Substituerede pyrazoler
CA2421493A1 (en)	2000-09-06	2002-03-14	Ortho-Mcneil Pharmaceutical, Inc.	A method for treating allergies using substituted pyrazoles
GB0025782D0 (en)	2000-10-20	2000-12-06	Pfizer Ltd	Use of inhibitors
EP1217000A1 (en)	2000-12-23	2002-06-26	Aventis Pharma Deutschland GmbH	Inhibitors of factor Xa and factor VIIa
GB0100621D0 (en)	2001-01-10	2001-02-21	Vernalis Res Ltd	Chemical compounds VI
GB0103926D0 (en)	2001-02-17	2001-04-04	Astrazeneca Ab	Chemical compounds
WO2002076953A1 (en)	2001-03-21	2002-10-03	Warner-Lambert Company Llc	New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
US6998408B2 (en)	2001-03-23	2006-02-14	Bristol-Myers Squibb Pharma Company	6-5, 6-6, or 6-7 Heterobicycles as factor Xa inhibitors
JP2002296731A (ja)	2001-03-30	2002-10-09	Fuji Photo Film Co Ltd	熱現像カラー画像記録材料
US6982274B2 (en)	2001-04-16	2006-01-03	Eisai Co., Ltd.	1H-indazole compound
DE60227794D1 (de)	2001-04-26	2008-09-04	Eisai R&D Man Co Ltd	Stickstoffhaltige verbindung mit kondensiertem ring und pyrazolylgruppe als substituent und medizinische zusammensetzung davon
AU2002253357B2 (en)	2001-04-30	2006-08-24	Glaxo Group Limited	Fused pyrimidines as antagonists of the corticotropin releasing factor (crf)
WO2002094825A1 (fr)	2001-05-22	2002-11-28	Banyu Pharmaceutical Co., Ltd.	Nouveau derive de spiropiperidine
US20030114448A1 (en)	2001-05-31	2003-06-19	Millennium Pharmaceuticals, Inc.	Inhibitors of factor Xa
BR0210028A (pt)	2001-06-19	2004-06-22	Warner Lambert Co	Agentes antibacterianos
AU2002315389A1 (en)	2001-06-21	2003-01-08	Ariad Pharmaceuticals, Inc.	Novel pyrazolo-and pyrrolo-pyrimidines and uses thereof
GB0115109D0 (en)	2001-06-21	2001-08-15	Aventis Pharma Ltd	Chemical compounds
WO2003000690A1 (en)	2001-06-25	2003-01-03	Aventis Pharmaceuticals Inc.	Synthesis of heterocyclic compounds employing microwave technology
WO2003009852A1 (en)	2001-07-24	2003-02-06	Merck & Co., Inc.	Tyrosine kinase inhibitors
ATE427935T1 (de)	2001-08-07	2009-04-15	Banyu Pharma Co Ltd	Spiro isobenzofurane als neuropeptid y rezeptor antagonisten
HUP0401982A3 (en)	2001-09-19	2012-09-28	Aventis Pharma Sa	Indolizine derivates, process for their preparation and pharmaceutical compositions containing the compounds
WO2003037347A1 (en)	2001-10-30	2003-05-08	Novartis Ag	Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
HUP0402106A3 (en)	2001-11-01	2009-07-28	Janssen Pharmaceutica Nv	Heteroaryl amines as glycogen synthase kinase 3 beta inhibitors, process for their preparation and pharmaceutical compositions containing them
PL370480A1 (en)	2001-11-07	2005-05-30	F.Hoffmann-La Roche Ag	Aminopyrimidines and pyridines
EP1456652A4 (en)	2001-11-13	2005-11-02	Dana Farber Cancer Inst Inc	IMMUNOCELL ACTIVATION MODULATING SUBSTANCES AND USE METHOD THEREFOR
GB0129476D0 (en)	2001-12-10	2002-01-30	Syngenta Participations Ag	Organic compounds
ME00230B (me)	2002-01-22	2011-02-10		2-(piridin -2-ilamino)-pirido(2,3-d) pirimidin-7-oni
WO2003075836A2 (en)	2002-03-05	2003-09-18	Merck Frosst Canada & Co.	Cathepsin cysteine protease inhibitors
US6815519B2 (en)	2002-03-22	2004-11-09	Chung-Shan Institute Of Science & Technology	Acidic fluorine-containing poly (siloxane amideimide) silica hybrids
BR0308937A (pt)	2002-04-03	2005-01-04	Hoffmann La Roche	Compostos imidazo fundidos
EP1506175B1 (en)	2002-05-15	2009-04-01	Janssen Pharmaceutica N.V.	N-substituted tricyclic 3-aminopyrazoles as pdgf receptor inhibitors
JP4499342B2 (ja)	2002-05-16	2010-07-07	株式会社カネカ	ＳｉＨ基を含有する含窒素有機系化合物の製造方法
MXPA04011557A (es)	2002-05-23	2005-07-05	Chiron Corp	Compuestos de quinazolinona sustituida.
AR037647A1 (es)	2002-05-29	2004-12-01	Novartis Ag	Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina
US7119111B2 (en)	2002-05-29	2006-10-10	Amgen, Inc.	2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use
US7105526B2 (en)	2002-06-28	2006-09-12	Banyu Pharmaceuticals Co., Ltd.	Benzimidazole derivatives
GB0215676D0 (en)	2002-07-05	2002-08-14	Novartis Ag	Organic compounds
PA8577501A1 (es)	2002-07-25	2004-02-07	Warner Lambert Co	Inhibidores de quinasas
DK1534286T3 (da)	2002-07-29	2010-04-26	Rigel Pharmaceuticals Inc	Fremgangsmåder til behandling eller forebyggelse af autoimmune sygdomme med 2,4-pyrimidindiamin-forbindelser
ES2293064T3 (es)	2002-08-06	2008-03-16	F. Hoffmann-La Roche Ag	6-alcoxi-pirido-pirimidinas como inhibidores de la p-38 map quinasa.
EP1388541A1 (en)	2002-08-09	2004-02-11	Centre National De La Recherche Scientifique (Cnrs)	Pyrrolopyrazines as kinase inhibitors
US7084270B2 (en)	2002-08-14	2006-08-01	Hoffman-La Roche Inc.	Pyrimido compounds having antiproliferative activity
GB0220187D0 (en)	2002-08-30	2002-10-09	Novartis Ag	Organic compounds
GB0223349D0 (en)	2002-10-08	2002-11-13	Merck Sharp & Dohme	Therapeutic agents
TW200413381A (en)	2002-11-04	2004-08-01	Hoffmann La Roche	Novel amino-substituted dihydropyrimido [4,5-d]pyrimidinone derivatives, their manufacture and use as pharmaceutical agents
US7129351B2 (en)	2002-11-04	2006-10-31	Hoffmann-La Roche Inc.	Pyrimido compounds having antiproliferative activity
WO2004043367A2 (en)	2002-11-06	2004-05-27	Bristol-Myers Squibb Company	Fused heterocyclic compounds and use thereof
TWI335913B (en)	2002-11-15	2011-01-11	Vertex Pharma	Diaminotriazoles useful as inhibitors of protein kinases
AU2003283393A1 (en)	2002-11-18	2004-06-15	F. Hoffmann-La Roche Ag	Diazinopyrimidines
KR20050084027A (ko)	2002-11-28	2005-08-26	쉐링 악티엔게젤샤프트	Ｃｈｋ-, ｐｄｋ- 및 ａｋｔ-억제성 피리미딘, 그의제조방법 및 약제로서의 그의 용도
EP1567497B1 (en)	2002-12-06	2009-09-23	Purdue Research Foundation	Pyridines for treating injured mammalian nerve tissue
EP1571146A4 (en)	2002-12-10	2010-09-01	Ono Pharmaceutical Co	NITROGENIC HETEROCYCLIC COMPOUNDS AND THEIR MEDICAL USE
UA80171C2 (en)	2002-12-19	2007-08-27	Pfizer Prod Inc	Pyrrolopyrimidine derivatives
US7098332B2 (en)	2002-12-20	2006-08-29	Hoffmann-La Roche Inc.	5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
UA80767C2 (en)	2002-12-20	2007-10-25	Pfizer Prod Inc	Pyrimidine derivatives for the treatment of abnormal cell growth
EP1576014B1 (en)	2002-12-23	2011-06-29	Wyeth LLC	Antibodies against pd-1 and uses thereof
JP2004203749A (ja)	2002-12-24	2004-07-22	Kanegafuchi Chem Ind Co Ltd	ＳｉＨ基を含有する含窒素有機系化合物の製造方法
EP1590341B1 (en)	2003-01-17	2009-06-17	Warner-Lambert Company LLC	2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
GB0305929D0 (en)	2003-03-14	2003-04-23	Novartis Ag	Organic compounds
US7135469B2 (en)	2003-03-18	2006-11-14	Bristol Myers Squibb, Co.	Linear chain substituted monocyclic and bicyclic derivatives as factor Xa inhibitors
US20040242566A1 (en)	2003-03-25	2004-12-02	Syrrx, Inc.	Dipeptidyl peptidase inhibitors
GB0308208D0 (en)	2003-04-09	2003-05-14	Glaxo Group Ltd	Chemical compounds
MXPA05010765A (es)	2003-04-10	2005-12-12	Hoffmann La Roche	Compuestos pirimido.
KR100767272B1 (ko)	2003-05-05	2007-10-17	에프. 호프만-라 로슈 아게	Ｃｒｆ 활성을 갖는 융합 피리미딘 유도체
JP2004346145A (ja)	2003-05-21	2004-12-09	Teijin Ltd	イミド組成物およびそれからなる樹脂組成物、及びその製造方法
AU2004249120B2 (en)	2003-05-23	2008-07-24	Glaxosmithkline	Guanidino-substituted quinazolinone compounds as MC4-R agonists
ES2341545T3 (es)	2003-06-06	2010-06-22	Arexis Ab	Uso de compuestos heterociclicos condensados como inhibidores de scce para el tratamiento de enfermedades de la piel.
IL156495A0 (en)	2003-06-17	2004-01-04	Prochon Biotech Ltd	Use of fgfr3 antagonists for treating t cell mediated diseases
JP4631703B2 (ja)	2003-06-18	2011-02-16	宇部興産株式会社	ピリミジン−４−オン化合物の製造方法
JP2005015395A (ja)	2003-06-26	2005-01-20	Japan Science & Technology Agency	新規ピリミドピリミジンヌクレオシドとその構造類縁体
CN1984660B (zh)	2003-07-03	2010-12-15	美瑞德生物工程公司	作为天冬氨酸特异性半胱氨酸蛋白酶活化剂和细胞程序死亡诱导剂的4-芳基氨基-喹唑啉
AR045037A1 (es)	2003-07-10	2005-10-12	Aventis Pharma Sa	Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
CA2533774A1 (en)	2003-07-29	2005-02-10	Irm Llc	Compounds and compositions as protein kinase inhibitors
US7390820B2 (en)	2003-08-25	2008-06-24	Amgen Inc.	Substituted quinolinone derivatives and methods of use
US20050070542A1 (en)	2003-09-03	2005-03-31	Hodgetts Kevin J.	5-Aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds
CN101906106A (zh)	2003-09-18	2010-12-08	康福玛医药公司	作为hsp90-抑制剂的新的杂环化合物
AU2004274493A1 (en)	2003-09-19	2005-03-31	Gilead Sciences, Inc.	Aza-quinolinol phosphonate integrase inhibitor compounds
AR045944A1 (es)	2003-09-24	2005-11-16	Novartis Ag	Derivados de isoquinolina 1.4-disustituidas
CA2540647C (en)	2003-10-01	2012-07-10	Bayer Healthcare Ag	Tetrahydro-naphthalene and urea derivatives
BRPI0415210A (pt) *	2003-10-08	2006-12-05	Irm Llc	compostos e composições como inibidores de proteìna cinase
US20090099165A1 (en)	2003-10-14	2009-04-16	Arizona Board Of Regents On Behalf Of The University Of Arizona	Protein Kinase Inhibitors
CN1897950A (zh)	2003-10-14	2007-01-17	惠氏公司	稠合芳基和杂芳基衍生物及其使用方法
BRPI0416656A (pt)	2003-11-17	2007-01-16	Pfizer Prod Inc	compostos de pirrolopirimidina úteis no tratamento do cáncer
WO2005056524A2 (en)	2003-12-09	2005-06-23	Euro-Celtique S.A.	Therapeutic agents useful for treating pain
WO2005066162A1 (en)	2003-12-23	2005-07-21	Human Biomolecular Research Institute	Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer
KR100703068B1 (ko)	2003-12-30	2007-04-05	에스케이케미칼주식회사	피리딘 유도체와 이의 제조방법, 및 이를 포함하는약제조성물
US20050222171A1 (en)	2004-01-22	2005-10-06	Guido Bold	Organic compounds
ES2333730T3 (es)	2004-01-23	2010-02-26	Janssen Pharmaceutica Nv	Derivados de quinolina y uso de los mismos como inhibidores de micobacterias.
JP2007524673A (ja)	2004-01-23	2007-08-30	アムジエン・インコーポレーテツド	バニロイド受容体リガンドと治療におけるその使用
JP2007529422A (ja)	2004-01-29	2007-10-25	エリクシアーファーマシューティカルズ，インコーポレイテッド	抗ウイルス治療
GB0402137D0 (en)	2004-01-30	2004-03-03	Smithkline Beecham Corp	Novel compounds
AU2005214352B2 (en)	2004-02-14	2009-11-12	Irm Llc	Compounds and compositions as protein kinase inhibitors
BRPI0507852A (pt)	2004-02-18	2007-07-10	Warner Lambert Co	2-(piridin-3-ilamino)-pirido[2,3-d]pirimidin-7-onas
JP2007523938A (ja)	2004-02-27	2007-08-23	エフ．ホフマン−ラ　ロシュ　アーゲー	ピラゾールの縮合誘導体
JP2007523936A (ja)	2004-02-27	2007-08-23	エフ．ホフマン−ラ　ロシュ　アーゲー	ヘテロアリール縮合ピラゾロ誘導体
US20080004263A1 (en)	2004-03-04	2008-01-03	Santora Vincent J	Ligands of Follicle Stimulating Hormone Receptor and Methods of Use Thereof
US20070197510A1 (en)	2004-03-10	2007-08-23	Kazuyuki Ohmoto	Nitriles and medicinal compositions containing the same as the active ingredient
EP1736476A4 (en)	2004-03-29	2010-04-07	Mitsui Chemicals Inc	NEW CONNECTION AND ORGANIC ELECTRONIC DEVICE USING SUCH A CONNECTION
WO2005105097A2 (en) *	2004-04-28	2005-11-10	Gpc Biotech Ag	Pyridopyrimidines for treating inflammatory and other diseases
JP2005320288A (ja)	2004-05-10	2005-11-17	Mitsui Chemicals Inc	テトラカルボン酸誘導体、および該化合物を用いた電子写真感光体、電子写真装置
US20050256309A1 (en)	2004-05-12	2005-11-17	Altenbach Robert J	Tri-and bi-cyclic heteroaryl histamine-3 receptor ligands
EP1773836B1 (en)	2004-05-27	2012-09-05	Pfizer Products Inc.	Pyrrolopyrimidine derivatives useful in cancer treatment
EP1761539A1 (en)	2004-06-02	2007-03-14	Takeda Pharmaceutical Company Limited	Indole derivative and use for treatment of cancer
PE20060426A1 (es)	2004-06-02	2006-06-28	Schering Corp	DERIVADOS DE ACIDO TARTARICO COMO INHIBIDORES DE MMPs, ADAMs, TACE Y TNF-alfa
EP1758892B1 (en)	2004-06-10	2012-10-17	Irm Llc	Compounds and compositions as protein kinase inhibitors
PT1761528E (pt)	2004-06-11	2008-04-15	Japan Tobacco Inc	Derivados de 5-amino-2,4,7-trioxo-3,4,7,8-tetra-hidro-2hpirido[ 2,3-d]pirimidina e compostos relacionados para o tratamento do cancro
GB0512324D0 (en)	2005-06-16	2005-07-27	Novartis Ag	Organic compounds
JP2006028027A (ja)	2004-07-12	2006-02-02	Mitsui Chemicals Inc	テトラカルボン酸誘導体、および該化合物を用いた電子写真感光体、電子写真装置
KR100853975B1 (ko)	2004-08-31	2008-08-25	에프. 호프만-라 로슈 아게	3-페닐 디히드로피리미도[4,5-ｄ]피리미디논의 아미드유도체, 이의 제조 방법 및 약제로서의 용도
CA2576924A1 (en)	2004-08-31	2006-03-09	F. Hoffmann-La Roche Ag	Amide derivatives of 7-amino-3-phenyl-dihydropyrimido [4,5-d]pyrimidinones, their manufacture and use as pharmaceutical agents
CA2577275A1 (en)	2004-08-31	2006-03-09	Astrazeneca Ab	Quinazolinone derivatives and their use as b-raf inhibitors
DE102004042667A1 (de)	2004-09-01	2006-03-30	Ewald Dörken Ag	Mehrschichtige Gebäudewand
US7687113B2 (en)	2004-09-10	2010-03-30	Ube Industries, Inc.	Modified polyimide resin and curable resin composition
US20080064680A1 (en)	2004-09-14	2008-03-13	Bamdad Cynthia C	Methods for Diagnosis and Treatment of Cancer
GB0420719D0 (en)	2004-09-17	2004-10-20	Addex Pharmaceuticals Sa	Novel allosteric modulators
WO2006038112A1 (en)	2004-10-01	2006-04-13	Warner-Lambert Company Llc	Use of kinase inhibitors to promote neochondrogenesis
FR2876582B1 (fr)	2004-10-15	2007-01-05	Centre Nat Rech Scient Cnrse	Utilisation de derives de pyrrolo-pyrazines pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules
US20060135553A1 (en)	2004-10-28	2006-06-22	Campbell David A	Imidazole derivatives
US7855205B2 (en)	2004-10-29	2010-12-21	Janssen Pharmaceutica Nv	Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
CA2587276A1 (en)	2004-11-08	2006-05-18	Baxter International Inc.	Nanoparticulate compositions of tubulin inhibitor compounds
WO2006055752A2 (en)	2004-11-18	2006-05-26	Incyte Corporation	INHIBITORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1 AND METHODS OF USING THE SAME
EP1814882A1 (en)	2004-11-22	2007-08-08	Vertex Pharmaceuticals Incorporated	Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases
BRPI0517887A (pt)	2004-11-24	2008-10-21	Novartis Ag	combinações de inibidores de jaks
MY140748A (en)	2004-12-06	2010-01-15	Astrazeneca Ab	Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
JP5111113B2 (ja)	2004-12-13	2012-12-26	サネシスファーマシューティカルズ，インコーポレイテッド	Ｒａｆキナーゼ阻害剤として有用なピリドピリミジノン、ジヒドロピリミドピリミジノンおよびプテリジノン
WO2006074293A2 (en)	2005-01-07	2006-07-13	President And Fellows Of Harvard College	Bicyclic dihydropyrimidines as eg5 inhibitors
DE102005008310A1 (de)	2005-02-17	2006-08-24	Schering Ag	Verwendung von CDKII Inhibitoren zur Fertilitätskontrolle
BRPI0607402A2 (pt)	2005-03-01	2009-09-01	Pfizer Ltd	uso de inibidores de pde7 para o tratamento de dor neuropática
US7402596B2 (en)	2005-03-24	2008-07-22	Renovis, Inc.	Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
WO2006105448A2 (en)	2005-03-30	2006-10-05	Minerva Biotechnologies Corporation	Proliferation of muc1 expressing cells
JP2006284843A (ja)	2005-03-31	2006-10-19	Mitsui Chemicals Inc	テトラカルボン酸誘導体を用いた電子写真感光体、電子写真装置
US20060223993A1 (en)	2005-04-01	2006-10-05	Connor Daniel M	Colorant compounds, intermediates, and compositions
JP2006316054A (ja)	2005-04-15	2006-11-24	Tanabe Seiyaku Co Ltd	高コンダクタンス型カルシウム感受性ｋチャネル開口薬
KR100781704B1 (ko)	2005-04-20	2007-12-03	에스케이케미칼주식회사	피리딘 유도체와 이의 제조방법, 및 이를 포함하는약제조성물
EP1885369B1 (en)	2005-05-04	2015-09-23	Evotec AG	Fused heterocyclic compounds, and compositions and uses thereof
PT2161336E (pt)	2005-05-09	2013-10-03	Ono Pharmaceutical Co	Anticorpos monoclonais humanos para morte programada 1 (pd-1) e métodos de tratamento do cancro utilizando anticorpos anti- pd-1 sozinhos ou em combinação com outros agentes imunoterapêuticos¿
WO2006124731A2 (en) *	2005-05-12	2006-11-23	Irm Llc	Compounds and compositions as protein kinase inhibitors
WO2006124462A2 (en)	2005-05-13	2006-11-23	Irm, Llc	Compounds and compositions as protein kinase inhibitors
US20060279115A1 (en)	2005-06-09	2006-12-14	Ash Tisdelle	Vehicular head and neck safety system and method
GB0512844D0 (en)	2005-06-23	2005-08-03	Novartis Ag	Organic compounds
CN104356236B (zh)	2005-07-01	2020-07-03	E.R.施贵宝&圣斯有限责任公司	抗程序性死亡配体1(pd-l1)的人单克隆抗体
AU2006272876A1 (en)	2005-07-22	2007-02-01	Sunesis Pharmaceuticals, Inc.	Pyrazolo pyrimidines useful as aurora kinase inhibitors
EP1910369A1 (en)	2005-07-29	2008-04-16	Astellas Pharma Inc.	Fused heterocycles as lck inhibitors
ES2270715B1 (es)	2005-07-29	2008-04-01	Laboratorios Almirall S.A.	Nuevos derivados de pirazina.
ATE482958T1 (de)	2005-08-09	2010-10-15	Irm Llc	Verbindungen und zusammensetzungen als proteinkinaseinhibitoren
WO2007022268A2 (en)	2005-08-16	2007-02-22	Irm Llc	Compounds and compositions as protein kinase inhibitors
JP2009506004A (ja)	2005-08-25	2009-02-12	エフ．ホフマン−ラロシュアーゲー	ｐ３８ＭＡＰキナーゼ阻害剤としての縮合ピラゾール
US7678917B2 (en)	2005-09-01	2010-03-16	Hoffman-La Roche Inc.	Factor Xa inhibitors
US20080249301A1 (en)	2005-09-06	2008-10-09	Smithkline Beecham Corporation	Regioselective Process for Preparing Benzimidazole Thiophenes
AU2006289838B2 (en)	2005-09-15	2011-08-18	Aska Pharmaceutical Co., Ltd.	Heterocyclic compound, and production process and use thereof
US20070116984A1 (en)	2005-09-21	2007-05-24	Doosan Corporation	Spiro-compound for electroluminescent display device and electroluminescent display device comprising the same
US7482360B2 (en)	2005-09-23	2009-01-27	Schering Corporation	Fused tetracyclic mGluR1 antagonists as therapeutic agents
DE102005048072A1 (de)	2005-09-24	2007-04-05	Bayer Cropscience Ag	Thiazole als Fungizide
CA2624965A1 (en)	2005-10-07	2007-04-19	Exelixis, Inc.	Pyridopyrimidinone inhibitors of pi3k.alpha.
HRP20140975T1 (hr)	2005-10-07	2014-11-21	Exelixis, Inc.	Derivati n-(3-amino-hinoksalin-2-il)-sulfonamida i njihova uporaba kao inhibitora fosfatidilinozitol 3-kinaze
WO2007061554A2 (en)	2005-10-21	2007-05-31	Purdue Research Foundation	Dosage of 4-aminopyridine derivatives for treatment of central nervous system injuries
KR20080066821A (ko)	2005-10-26	2008-07-16	베링거 인겔하임 인터내셔날 게엠베하	Ｍｃｈ 길항 활성을 가진 (헤테로)아릴 화합물 및 당해화합물을 포함하는 약제
US8604042B2 (en)	2005-11-01	2013-12-10	Targegen, Inc.	Bi-aryl meta-pyrimidine inhibitors of kinases
US8067457B2 (en)	2005-11-01	2011-11-29	Millennium Pharmaceuticals, Inc.	Compounds useful as antagonists of CCR2
ES2595636T3 (es)	2005-11-01	2017-01-02	Targegen, Inc.	Inhibidores de cinasas de bi-aril-meta-pirimidina
EP1945222B1 (en)	2005-11-02	2012-12-26	Bayer Pharma Aktiengesellschaft	Pyrrolo[2,1-f] [1,2,4]-triazin-4-ylamines as igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases
US20070149508A1 (en)	2005-11-02	2007-06-28	Targegen, Inc.	Six membered heteroaromatic inhibitors targeting resistant kinase mutations
AU2006315514B2 (en)	2005-11-10	2012-03-01	Chemocentryx, Inc.	Substituted quinolones and methods of use
KR101318127B1 (ko)	2005-11-10	2013-10-16	엠에스디 가부시키가이샤	아자 치환된 스피로 유도체
WO2007058626A1 (en)	2005-11-16	2007-05-24	S*Bio Pte Ltd	Indazole compounds
EP1953147A1 (en)	2005-11-21	2008-08-06	Japan Tobacco, Inc.	Heterocyclic compound and medicinal application thereof
US8143393B2 (en)	2005-12-02	2012-03-27	Bayer Healthcare Llc	Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
PE20070855A1 (es)	2005-12-02	2007-10-14	Bayer Pharmaceuticals Corp	Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
BRPI0619514A2 (pt)	2005-12-08	2011-10-04	Millennium Pharm Inc	compostos bicìclicos com atividade inibidora cinase, composição farmacêutica contendo os mesmos e uso de ditos compostos
WO2007066189A2 (en)	2005-12-09	2007-06-14	Pfizer Products Inc.	Salts, prodrugs and formulations of 1-[5-(4-amino-7-isopropyl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2-methoxy-phenyl]-3-(2,4-dichloro-phenyl)-urea
US20080318989A1 (en)	2005-12-19	2008-12-25	Burdick Daniel J	Pyrimidine Kinase Inhibitors
SMP200800041B (it)	2005-12-21	2009-07-14	Novartis Ag	Derivati di pirimidinil-aril-urea attivi come-fgf-inibitori
US7998959B2 (en)	2006-01-12	2011-08-16	Incyte Corporation	Modulators of 11-β hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
UY30118A1 (es)	2006-01-31	2007-06-29	Tanabe Seiyaku Co	Compueto amina trisustituido
WO2007092879A2 (en)	2006-02-08	2007-08-16	Janssen Pharmaceutica, N.V.	Substituted thiatriazaacenaphthylene-6-carbonitrile kinase inhibitors
KR20080085232A (ko)	2006-02-17	2008-09-23	화이자 리미티드	Ｔｌｒ7 조절제로서 3-데아자퓨린 유도체
WO2007112347A1 (en)	2006-03-28	2007-10-04	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
WO2007110868A2 (en)	2006-03-28	2007-10-04	Atir Holding S.A.	Heterocyclic compounds and uses thereof in the treatment of sexual disorders
US20100273776A1 (en)	2006-03-29	2010-10-28	FOLDRx PHARMACEUTICALS, INC	Inhibition of alpha-synuclein toxicity
MX2008012912A (es)	2006-04-06	2008-11-26	Wisconsin Alumni Res Found	Analogos de 2-metilen-1a,25-dihidroxi-19,21-dinorvitamina d3 y sus usos.
WO2007120097A1 (en)	2006-04-13	2007-10-25	Astrazeneca Ab	Thioxanthine derivatives and their use as inhibitors of mpo
GB0608386D0 (en)	2006-04-27	2006-06-07	Senexis Ltd	Compounds
WO2007125405A2 (en)	2006-05-01	2007-11-08	Pfizer Products Inc.	Substituted 2-amino-fused heterocyclic compounds
PT2027123E (pt)	2006-05-11	2011-05-30	Irm Llc	Compostos e composi??es como inibidores da prote?na quinase
US20090312321A1 (en)	2006-05-15	2009-12-17	Irm Llc	Compositions and methods for fgf receptor kinases inhibitors
WO2007143600A2 (en)	2006-06-05	2007-12-13	Incyte Corporation	Sheddase inhibitors combined with cd30-binding immunotherapeutics for the treatment of cd30 positive diseases
DE102006027156A1 (de)	2006-06-08	2007-12-13	Bayer Schering Pharma Ag	Sulfimide als Proteinkinaseinhibitoren
WO2007147217A1 (en)	2006-06-22	2007-12-27	Prana Biotechnology Limited	Method of treatment of glioma brain tumour
TW200817391A (en)	2006-06-30	2008-04-16	Astrazeneca Ab	Novel compounds
US20090281115A1 (en)	2006-06-30	2009-11-12	Board of Regents, The University of Texas System, a Texas University	Inhibitors of c-kit and uses thereof
WO2008003766A2 (en)	2006-07-06	2008-01-10	Boehringer Ingelheim International Gmbh	4-heter0cycl0alkylpyri(mi)dines, process for the preparation thereof and their use as medicaments
WO2008008234A1 (en)	2006-07-07	2008-01-17	Targegen, Inc.	2-amino-5-substituted pyrimidine inhibitors
TW200811134A (en)	2006-07-12	2008-03-01	Irm Llc	Compounds and compositions as protein kinase inhibitors
WO2008012635A2 (en)	2006-07-26	2008-01-31	Pfizer Products Inc.	Amine derivatives useful as anticancer agents
WO2008021851A2 (en)	2006-08-09	2008-02-21	Smithkline Beecham Corporation	Novel compounds as antagonists or inverse agonists for opioid receptors
CA2658725A1 (en)	2006-08-16	2008-02-21	Exelixis, Inc.	Using pi3k and mek modulators in treatments of cancer
DE102006041382A1 (de)	2006-08-29	2008-03-20	Bayer Schering Pharma Ag	Carbamoyl-Sulfoximide als Proteinkinaseinhibitoren
CA2661842C (en)	2006-09-01	2017-08-22	Cylene Pharmaceuticals, Inc.	Tricyclic heteroaryl compounds and their use as serine-threonine protein kinases and parp modulators
EP2471529A3 (en)	2006-09-05	2012-10-10	Emory University	Kinase Inhibitors for Preventing or Treating Pathogen Infection and Method of Use Thereof
EP2270200A3 (en)	2006-09-11	2011-07-13	CGI Pharmaceuticals, Inc.	Kinase inhibitors, and methods of using and identifying kinase inhibitors
US7897762B2 (en)	2006-09-14	2011-03-01	Deciphera Pharmaceuticals, Llc	Kinase inhibitors useful for the treatment of proliferative diseases
WO2008034859A1 (en)	2006-09-21	2008-03-27	Boehringer Ingelheim International Gmbh	Glucopyranosyl-substituted difluorobenzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
US20100035917A1 (en)	2006-09-22	2010-02-11	Paul Bamborough	Pyrrolo[2,3-b]pyridin-4-yl-benzenesulfonamide compounds as 1kk2 inhibitors
KR20090073120A (ko)	2006-09-28	2009-07-02	노파르티스 아게	피라졸로[1,5-ａ]피리미딘 유도체 및 이들의 치료 용도
CN103739595A (zh)	2006-10-02	2014-04-23	Irm责任有限公司	作为蛋白激酶抑制剂的化合物和组合物
CL2007003100A1 (es)	2006-10-30	2008-04-18	Glaxo Group Ltd	Compuestos derivados de pirimidina, inhibidores de cisteina proteasa; procesos de preparacion; sales de los compuestos; composicion farmaceutica; y uso para el tratamiento de la malaria.
US7858645B2 (en)	2006-11-01	2010-12-28	Hoffmann-La Roche Inc.	Indazole derivatives
WO2008060907A2 (en)	2006-11-10	2008-05-22	Bristol-Myers Squibb Company	Pyrrolo-pyridine kinase inhibitors
US7892454B2 (en)	2006-11-17	2011-02-22	Polyera Corporation	Acene-based organic semiconductor materials and methods of preparing and using the same
EP2086974B1 (en)	2006-11-17	2013-07-24	Polyera Corporation	Diimide-based semiconductor materials and methods of preparing and using the same
KR20080045536A (ko)	2006-11-20	2008-05-23	에스케이케미칼주식회사	피리딘 화합물을 포함하는 간염 치료 및 예방 또는 간 보호효능을 갖는 약제 조성물
PT2497470E (pt)	2006-11-22	2016-02-22	Incyte Corp	Imidazotriazinas e imidazopirimidinas como inibidores de quinases
CN102123712B (zh)	2006-12-13	2014-03-19	默沙东公司	使用igf1r抑制剂治疗癌症的方法
WO2008071455A1 (en)	2006-12-15	2008-06-19	Bayer Schering Pharma Aktiengesellschaft	Bicyclic acyltryptophanols
WO2008074068A1 (en)	2006-12-20	2008-06-26	Prana Biotechnology Limited	Substituted quinoline derivatives as antiamyloidogeneic agents
US7737149B2 (en)	2006-12-21	2010-06-15	Astrazeneca Ab	N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
MX2009006704A (es)	2006-12-22	2009-06-30	Astex Therapeutics Ltd	Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
WO2008079933A2 (en)	2006-12-22	2008-07-03	Novartis Ag	Heteroaryl-heteroaryl compounds as cdk inhibitors for the treatment of cancer, inflammation and viral infections
AR064491A1 (es)	2006-12-22	2009-04-08	Astex Therapeutics Ltd	Derivados de imidazo[1, 2-a]pirimidina, un proceso para su preparacion, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por las quinasas fgfr.
FR2911140B1 (fr)	2007-01-05	2009-02-20	Sanofi Aventis Sa	Nouveaux derives de 2-anilino 4-heteroaryle pyrimides, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
US7893265B2 (en)	2007-01-08	2011-02-22	Polyera Corporation	Methods for preparing arene-BIS (dicarboximide)-based semiconducting materials and related intermediates for preparing same
CN101007778A (zh)	2007-01-10	2007-08-01	复旦大学	一种链延长型芴基双马来酰亚胺及其制备方法
KR20090106604A (ko)	2007-01-12	2009-10-09	아스텔라스세이야쿠 가부시키가이샤	축합 피리딘 화합물
EP2535345A1 (en)	2007-01-12	2012-12-19	BioCryst Pharmaceuticals, Inc.	Anticancer nucleoside analogs
FR2911604B1 (fr)	2007-01-19	2009-04-17	Sanofi Aventis Sa	Derives de n-(heteroaryl-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
JP5358962B2 (ja)	2007-02-06	2013-12-04	住友化学株式会社	組成物及び該組成物を用いてなる発光素子
JP2008198769A (ja)	2007-02-13	2008-08-28	Nippon Steel Chem Co Ltd	有機エレクトロルミネッセント素子
CA2678492A1 (en)	2007-03-06	2008-09-12	Novartis Ag	Bicyclic organic compounds suitable for the treatment of inflammatory or allergic conditions
JP2010520292A (ja)	2007-03-07	2010-06-10	アラントス・フアーマシユーテイカルズ・ホールデイング・インコーポレイテツド	複素環式部分を含有するメタロプロテアーゼ阻害剤
DK2152701T3 (en)	2007-03-12	2016-02-15	Ym Biosciences Australia Pty	Phenylaminopyrimidinforbindelser and uses thereof
US20080234262A1 (en)	2007-03-21	2008-09-25	Wyeth	Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
CA2679980A1 (en)	2007-03-21	2007-09-27	Epix Pharmaceuticals, Inc.	S1p receptor modulating compounds and use thereof
JP2010522177A (ja)	2007-03-23	2010-07-01	アムジエン・インコーポレーテツド	複素環化合物およびその使用
EP2896624B1 (en)	2007-03-28	2016-07-13	Atir Holding S.A.	Heterotricyclic compounds as serotonergic and/or dopaminergic agents and uses thereof
KR20080091948A (ko)	2007-04-10	2008-10-15	에스케이케미칼주식회사	락탐형 피리딘 화합물을 포함하는 허혈성 질환의 예방 및치료용 약학조성물
US20100112211A1 (en)	2007-04-12	2010-05-06	Advanced Technology Materials, Inc.	Zirconium, hafnium, titanium, and silicon precursors for ald/cvd
CN101754961A (zh)	2007-04-20	2010-06-23	先灵公司	嘧啶酮衍生物及其使用方法
EP1985612A1 (en)	2007-04-26	2008-10-29	Bayer Schering Pharma Aktiengesellschaft	Arymethylen substituted N-Acyl-gamma-aminoalcohols
EP1990342A1 (en)	2007-05-10	2008-11-12	AEterna Zentaris GmbH	Pyridopyrazine Derivatives, Process of Manufacturing and Uses thereof
CL2008001356A1 (es)	2007-05-10	2008-11-14	Smithkline Beecham Corp	Compuestos derivados de quinoxalina, inhibidores de la pi3 quinasa _(p13ka, pi3ko, pi3b y/o pi3ky); composicion farmaceutica; uso para tratar un trastorno autoinmune, enfermedad inflamatoria, cardiovascular, neurodegerativa, alergia, asma, enfermedad renal, cancer, rechazo de transplante, lesiones pulmonares.
WO2008144253A1 (en)	2007-05-14	2008-11-27	Irm Llc	Protein kinase inhibitors and methods for using thereof
GB2449293A (en)	2007-05-17	2008-11-19	Evotec	Compounds having Hsp90 inhibitory activity
JP5622568B2 (ja)	2007-06-03	2014-11-12	バンダービルトユニバーシティ	ベンズアミドｍＧｌｕＲ５の正のアロステリック調節因子ならびにその作製および使用方法
US8163752B2 (en)	2007-06-07	2012-04-24	Merck, Sharp & Dohme Corp.	Tricyclic anilide heterocyclic CGRP receptor antagonists
US8633186B2 (en)	2007-06-08	2014-01-21	Senomyx Inc.	Modulation of chemosensory receptors and ligands associated therewith
US7928111B2 (en)	2007-06-08	2011-04-19	Senomyx, Inc.	Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
CN101784551A (zh)	2007-06-15	2010-07-21	万有制药株式会社	二环苯胺衍生物
CN102131828B (zh)	2007-06-18	2015-06-17	默沙东有限责任公司	针对人程序性死亡受体pd-1的抗体
EP2018859A1 (en)	2007-07-26	2009-01-28	Bayer Schering Pharma Aktiengesellschaft	Arylmethylene substituted N-acyl-beta-amino alcohols
US8143253B2 (en)	2007-07-26	2012-03-27	Novartis Ag	Organic compounds
EP2020404A1 (en)	2007-08-01	2009-02-04	Bayer Schering Pharma Aktiengesellschaft	Cyanomethyl substituted N-Acyl Tryptamines
WO2009019518A1 (en)	2007-08-09	2009-02-12	Astrazeneca Ab	Pyrimidine compounds having a fgfr inhibitory effect
WO2009021083A1 (en)	2007-08-09	2009-02-12	Smithkline Beecham Corporation	Quinoxaline derivatives as pi3 kinase inhibitors
WO2009029625A1 (en)	2007-08-27	2009-03-05	Kalypsys, Inc.	4- [heterocyclyl-methyl] -8-fluoro-quinolin-2-ones useful as nitric oxide synthase inhibitors
US7960400B2 (en)	2007-08-27	2011-06-14	Duquesne University Of The Holy Ghost	Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof
CA2698511C (en)	2007-09-04	2016-10-11	The Scripps Research Institute	Substituted pyrimidinyl-amines as protein kinase inhibitors
WO2009030871A1 (en)	2007-09-07	2009-03-12	Vernalis R & D Ltd	Pyrrolopyrimidine derivatives having hsp90 inhibitory activity
TW200920357A (en)	2007-09-10	2009-05-16	Curis Inc	HSP90 inhibitors containing a zinc binding moiety
MX2010003606A (es)	2007-10-01	2010-07-02	Isis Pharmaceuticals Inc	Modulacion antisentido de la expresion del receptor del factor de crecimiento fibroblastico 4.
ES2549084T3 (es)	2007-10-05	2015-10-22	Msd K.K.	Derivados de benzoxazinona
US20100298289A1 (en)	2007-10-09	2010-11-25	Ucb Pharma, S.A.	Heterobicyclic compounds as histamine h4-receptor antagonists
WO2009049018A1 (en)	2007-10-10	2009-04-16	Syndax Pharmaceuticals, Inc.	Novel compounds and methods of using them
US8513233B2 (en)	2007-10-11	2013-08-20	Shanghai Institute Of Materia Medica, Cas	Pyrimidinyl-propionic acid derivatives and their use as PPAR agonists
GB0720038D0 (en)	2007-10-12	2007-11-21	Astex Therapeutics Ltd	New compounds
GB0720041D0 (en)	2007-10-12	2007-11-21	Astex Therapeutics Ltd	New Compounds
WO2009047993A1 (ja)	2007-10-13	2009-04-16	Konica Minolta Holdings, Inc.	有機エレクトロルミネッセンス素子、表示装置及び照明装置
BRPI0817681A2 (pt)	2007-10-16	2015-04-14	Wyeth Llc	Compostos de tienopirimidina e pirazolopirimidina e seu uso como inibidores de mtor quinase e pi3 quinase
EP2212323B1 (en)	2007-10-17	2012-08-15	Novartis AG	Imidazo [1,2-a] pyridine derivatives useful as alk inhibitors
RU2007139634A (ru)	2007-10-25	2009-04-27	Сергей Олегович Бачурин (RU)	Новые тиазол-, триазол- или оксадиазол-содержащие тетрациклические соединения
ATE523508T1 (de)	2007-10-25	2011-09-15	Astrazeneca Ab	Für die behandlung von zellproliferativen erkrankungen geeignete pyridin- und pyrazinderivate
WO2009056886A1 (en)	2007-11-01	2009-05-07	Astrazeneca Ab	Pyrimidine derivatives and their use as modulators of fgfr activity
CN104311563B (zh)	2007-11-28	2016-12-07	达那-法伯癌症研究所	Bcr-abl的小分子豆蔻酸酯抑制剂及其使用方法
EP2231620A1 (en)	2007-12-03	2010-09-29	Boehringer Ingelheim International GmbH	Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation
CA2709202C (en)	2007-12-19	2013-04-23	Amgen Inc.	Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
CA2710458A1 (en)	2007-12-21	2009-07-09	Wyeth Llc	Imidazo [1,2-b] pyridazine compounds as modulators of liver x receptors
WO2009086303A2 (en)	2007-12-21	2009-07-09	University Of Rochester	Method for altering the lifespan of eukaryotic organisms
WO2009086509A2 (en)	2007-12-27	2009-07-09	Purdue Research Foundation	Reagents for biomolecular labeling, detection and quantification employing raman spectroscopy
FR2926297B1 (fr)	2008-01-10	2013-03-08	Centre Nat Rech Scient	Molecules chimiques inhibitrices du mecanisme d'epissage pour traiter des maladies resultant d'anomalies d'epissage.
EA201001205A1 (ru)	2008-01-24	2011-04-29	Юсб Фарма, С.А.	Соединения, содержащие циклобутоксигруппу
KR20100119776A (ko)	2008-01-24	2010-11-10	알라 캠, 엘엘씨	2-알킬아미노-3-아릴설포닐-사이클로알카노[ｅ 또는 ｄ]피라졸로[1,5-Ａ]피리미딘/세로토닌 5-ＨＴ6 수용체의 길항제, 이의 제조방법 및 이의 용도
WO2009093210A2 (ru)	2008-01-24	2009-07-30	Alla Chem, Llc	ЗАМЕЩЕННЫЕ ЦИKЛOAЛKAHO[e ИЛИ d]ПИPAЗOЛO[l,5-a]ПИPИMИДИHЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT6 РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
US7964608B2 (en)	2008-01-25	2011-06-21	High Point Pharmaceuticals, Llc	Tricyclic compounds as modulators of TNF-α synthesis
JP5608099B2 (ja)	2008-01-30	2014-10-15	ジェネンテック，インコーポレイテッド	ピラゾロピリミジンｐｉ３ｋ阻害剤化合物および使用方法
WO2009099982A1 (en)	2008-02-04	2009-08-13	Osi Pharmaceuticals, Inc.	2-aminopyridine kinase inhibitors
WO2009103652A1 (en)	2008-02-22	2009-08-27	F. Hoffmann-La Roche Ag	Modulators for amyloid beta
CN102007126A (zh)	2008-02-22	2011-04-06	Irm责任有限公司	作为gpr119活性调控剂的化合物和组合物
CA2716128A1 (en)	2008-02-27	2009-09-03	Vitae Pharmaceuticals, Inc.	Inhibitors of 11.beta.-hydroxysteroid dehydrogenase type 1
WO2009108827A1 (en)	2008-02-29	2009-09-03	Wyeth	Fused tricyclic pyrazolo[1, 5-a]pyrimidines, methods for preparation and uses thereof
ITTV20080039A1 (it)	2008-03-06	2009-09-07	Alpinestars Research Srl	Collare di protezione in particolare per guidatori di motoveicoli
WO2009114335A2 (en)	2008-03-12	2009-09-17	Merck & Co., Inc.	Pd-1 binding proteins
GB0804701D0 (en)	2008-03-13	2008-04-16	Amura Therapeutics Ltd	Compounds
WO2009114870A2 (en)	2008-03-14	2009-09-17	Intellikine, Inc.	Kinase inhibitors and methods of use
US8993580B2 (en)	2008-03-14	2015-03-31	Intellikine Llc	Benzothiazole kinase inhibitors and methods of use
WO2009146034A2 (en)	2008-03-31	2009-12-03	Takeda Pharmaceutical Company Limited	Mapk/erk kinase inhibitors and methods of use thereof
WO2009122180A1 (en)	2008-04-02	2009-10-08	Medical Research Council	Pyrimidine derivatives capable of inhibiting one or more kinases
US8436005B2 (en)	2008-04-03	2013-05-07	Abbott Laboratories	Macrocyclic pyrimidine derivatives
ATE531372T1 (de)	2008-04-07	2011-11-15	Amgen Inc	Gem-disubstituierte und spirocyclische aminopyridine/pyrimidine als zellcyclus- inhibitoren
WO2009124755A1 (en)	2008-04-08	2009-10-15	European Molecular Biology Laboratory (Embl)	Compounds with novel medical uses and method of identifying such compounds
WO2009125808A1 (ja)	2008-04-11	2009-10-15	第一三共株式会社	アミノシクロヘキシル誘導体
WO2009125809A1 (ja)	2008-04-11	2009-10-15	第一三共株式会社	ピペリジン誘導体
EP2277881A4 (en)	2008-04-18	2011-09-07	Shionogi & Co	HETEROCYCLIC COMPOUND HAVING INHIBITORY ACTIVITY ON P13K
JP2011518219A (ja)	2008-04-22	2011-06-23	ポートラファーマシューティカルズ，インコーポレイテッド	タンパク質キナーゼの阻害剤
US8309577B2 (en)	2008-04-23	2012-11-13	Bristol-Myers Squibb Company	Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands
US7863291B2 (en)	2008-04-23	2011-01-04	Bristol-Myers Squibb Company	Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
CA2720888A1 (en)	2008-04-29	2009-11-05	Novartis Ag	Methods of monitoring the modulation of the kinase activity of fibroblast growth factor receptor and uses of said methods
CA2719868A1 (en)	2008-04-29	2009-11-05	F. Hoffmann-La Roche Ag	Pyrimidinyl pyridone inhibitors of jnk.
WO2009133127A1 (en)	2008-04-30	2009-11-05	Merck Serono S.A.	Fused bicyclic compounds and use thereof as pi3k inhibitors
US9315449B2 (en)	2008-05-15	2016-04-19	Duke University	Substituted pyrazoles as heat shock transcription factor activators
CA2725185C (en)	2008-05-23	2016-10-25	Novartis Ag	Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors
WO2009144205A1 (en)	2008-05-30	2009-12-03	Basf Se	Rylene-based semiconductor materials and methods of preparation and use thereof
WO2009148916A1 (en)	2008-06-03	2009-12-10	Merck & Co., Inc.	Inhibitors of akt activity
US8377332B2 (en)	2008-06-10	2013-02-19	Basf Se	Transition metal complexes and use thereof in organic light emitting diodes—III
FR2932600B1 (fr)	2008-06-11	2010-06-04	Areva Np	Embout inferieur d'assemblage de combustible nucleaire
US8507504B2 (en)	2008-06-12	2013-08-13	Merck Sharp & Dohme Corp.	Process for producing bicycloaniline derivatives
GB0810902D0 (en)	2008-06-13	2008-07-23	Astex Therapeutics Ltd	New compounds
CN102123989A (zh)	2008-06-19	2011-07-13	阿斯利康(瑞典)有限公司	吡唑化合物436
US8575337B2 (en)	2008-06-24	2013-11-05	Research Foundation Itsuu Laboratory	Oxazolidinone derivative having fused ring
US8338439B2 (en)	2008-06-27	2012-12-25	Celgene Avilomics Research, Inc.	2,4-disubstituted pyrimidines useful as kinase inhibitors
NZ590320A (en)	2008-07-14	2012-12-21	Gilead Sciences Inc	Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases
WO2010006947A1 (en)	2008-07-15	2010-01-21	F. Hoffmann-La Roche Ag	Novel phenyl-imidazopyridines and pyridazines
WO2010007099A1 (en)	2008-07-15	2010-01-21	Cellzome Limited	2-aminoimidazo[1,2-b]pyridazine derivatives as pi3k inhibitors
UY31982A (es)	2008-07-16	2010-02-26	Boehringer Ingelheim Int	Derivados de 1,2-dihidropiridin-3-carboxamidas n-sustituidas
CN102159572A (zh)	2008-07-16	2011-08-17	先灵公司	双环杂环衍生物及其作为gpr 119调节剂的用途
EP2328897A1 (en)	2008-07-16	2011-06-08	Schering Corporation	Bicyclic heterocycle derivatives and their use as gpcr modulators
WO2010009735A2 (en)	2008-07-23	2010-01-28	Dako Denmark A/S	Combinatorial analysis and repair
WO2010017047A1 (en)	2008-08-05	2010-02-11	Merck & Co., Inc.	Therapeutic compounds
WO2010015643A1 (en)	2008-08-06	2010-02-11	Novartis Ag	New antiviral modified nucleosides
AU2009282480B2 (en)	2008-08-11	2015-05-07	Children's Medical Center Corporation	Halofuginone analogs for inhibition of tRNA synthetases and uses thereof
UY32049A (es)	2008-08-14	2010-03-26	Takeda Pharmaceutical	Inhibidores de cmet
WO2010030027A1 (en)	2008-09-10	2010-03-18	Mitsubishi Tanabe Pharma Corporation	Aromatic nitrogen-containing 6-membered ring compounds and their use
KR101924874B1 (ko)	2008-09-26	2018-12-04	다나-파버 캔서 인스티튜트 인크.	인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도
AR073760A1 (es)	2008-10-03	2010-12-01	Astrazeneca Ab	Derivados heterociclicos y metodos de uso de los mismos
US20100267748A1 (en)	2008-10-15	2010-10-21	Gilead Palo Alto, Inc.	HETEROCYCLIC COMPOUNDS USEFUL AS STEAROYL CoA DESATURASE INHIBITORS
US8110578B2 (en)	2008-10-27	2012-02-07	Signal Pharmaceuticals, Llc	Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
US20100105655A1 (en)	2008-10-29	2010-04-29	Astrazeneca Ab	Novel compounds 515
US8476431B2 (en)	2008-11-03	2013-07-02	Itellikine LLC	Benzoxazole kinase inhibitors and methods of use
WO2010052448A2 (en)	2008-11-05	2010-05-14	Ucb Pharma S.A.	Fused pyrazine derivatives as kinase inhibitors
WO2010059552A1 (en)	2008-11-18	2010-05-27	Glaxosmithkline Llc	Prolyl hydroxylase inhibitors
JP5743897B2 (ja)	2008-11-20	2015-07-01	グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅＬＬＣ	化合物
JP5522053B2 (ja)	2008-12-03	2014-06-18	コニカミノルタ株式会社	有機エレクトロルミネッセンス素子、有機エレクトロルミネッセンス素子材料、表示装置及び照明装置
KR101061599B1 (ko)	2008-12-05	2011-09-02	한국과학기술연구원	비정상 세포 성장 질환의 치료를 위한 단백질 키나아제 저해제인 신규 인다졸 유도체, 이의 약학적으로 허용가능한염 및 이를 유효성분으로 함유하는 약학적 조성물
CN106336400A (zh)	2008-12-08	2017-01-18	萌蒂制药国际有限公司	酪氨酸激酶蛋白受体拮抗剂
FI4209510T3 (fi)	2008-12-09	2024-03-22	Hoffmann La Roche	Anti-PD-L1-vasta-aineita ja niiden käyttö T-solutoiminnan tehostamiseksi
US8110265B2 (en)	2008-12-09	2012-02-07	The Coca-Cola Company	Pet container and compositions having enhanced mechanical properties and gas barrier properties
WO2010067886A1 (en)	2008-12-12	2010-06-17	Banyu Pharmaceutical Co.,Ltd.	Dihydropyrimidopyrimidine derivative
EP2376494A4 (en)	2008-12-12	2012-07-11	Msd Kk	DIHYDROPYRIMIDOPYRIMIDINDERIVATE
NZ593537A (en)	2008-12-19	2013-07-26	Genentech Inc	Isoquinoline derivatives and methods of use
JO2885B1 (en)	2008-12-22	2015-03-15	ايلي ليلي اند كومباني	Protein kinase inhibitors
EP2379506B1 (en)	2008-12-30	2015-09-02	ArQule, Inc.	Substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds
TW201035098A (en)	2008-12-30	2010-10-01	Arqule Inc	Substituted imidazolyl-5,6-dihydrobenzo[n] isoquinoline compounds
CA2748181C (en)	2009-01-06	2019-07-16	Nathanael S. Gray	Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
JOP20190230A1 (ar)	2009-01-15	2017-06-16	Incyte Corp	طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
EP2387315B1 (en)	2009-01-16	2015-07-15	Merck Sharp & Dohme Corp.	IMIDAZO[1,2-a]PYRIDINES AND IMIDAZO[1,2-b]PYRIDAZINES AS MARK INHIBITORS
DE102009007038A1 (de)	2009-02-02	2010-08-05	Merck Patent Gmbh	Metallkomplexe
JP2010180147A (ja)	2009-02-04	2010-08-19	Mitsubishi Gas Chemical Co Inc	シアン酸エステル化合物、およびその硬化物
EP2393835B1 (en)	2009-02-09	2017-04-05	Université d'Aix-Marseille	Pd-1 antibodies and pd-l1 antibodies and uses thereof
TW201038569A (en)	2009-02-16	2010-11-01	Abbott Gmbh & Co Kg	Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
TW201035102A (en)	2009-03-04	2010-10-01	Gruenethal Gmbh	Sulfonylated tetrahydroazolopyrazines and their use as medicinal products
WO2010103306A1 (en)	2009-03-10	2010-09-16	Astrazeneca Uk Limited	Benzimidazole derivatives and their use as antivaral agents
JP5615261B2 (ja)	2009-03-11	2014-10-29	学校法人関西学院	多環芳香族化合物
EP2408766A1 (en)	2009-03-18	2012-01-25	Schering Corporation	Bicyclic compounds as inhibitors of diacylglycerol acyltransferase
CN102438660A (zh)	2009-03-23	2012-05-02	美国西门子医疗解决公司	用于检测神经障碍的显像剂
ES2540119T3 (es)	2009-03-27	2015-07-08	Abbvie Inc.	Compuestos como ligandos de receptores cannabinoides
WO2010117425A1 (en)	2009-03-31	2010-10-14	Biogen Idec Ma Inc.	Certain substituted pyrimidines, pharmaceutical compositions thereof, and methods for their use
JP5629752B2 (ja)	2009-04-06	2014-11-26	ユニバーシティ・ヘルス・ネットワークＵｎｉｖｅｒｓｉｔｙＨｅａｌｔｈＮｅｔｗｏｒｋ	キナーゼインヒビターおよびこれを用いた癌の治療方法
KR101675607B1 (ko)	2009-04-07	2016-11-11	에머리티 파마 아베	치료제로서 이소옥사졸-3(2ｈ)-온 유사체
GB0906470D0 (en)	2009-04-15	2009-05-20	Astex Therapeutics Ltd	New compounds
GB0906472D0 (en)	2009-04-15	2009-05-20	Astex Therapeutics Ltd	New compounds
JP5531446B2 (ja)	2009-04-20	2014-06-25	コニカミノルタ株式会社	有機エレクトロルミネッセンス素子、有機エレクトロルミネッセンス素子材料、表示装置および照明装置
WO2010126960A1 (en)	2009-04-29	2010-11-04	Locus Pharmaceuticals, Inc.	Pyrrolotriazine compounds
ES2347630B1 (es)	2009-04-29	2011-09-08	Universitat Ramon Llull	Sintesis y usos de 4-cianopentanoatos y 4-cianopentenoatos sustituidos.
WO2010127212A1 (en)	2009-04-30	2010-11-04	Forest Laboratories Holdings Limited	Inhibitors of acetyl-coa carboxylase
JO2860B1 (en)	2009-05-07	2015-03-15	ايلي ليلي اند كومباني	Phenylendazolyl compounds
JP5600891B2 (ja)	2009-05-15	2014-10-08	コニカミノルタ株式会社	有機エレクトロルミネッセンス素子、表示装置および照明装置
JP5604808B2 (ja)	2009-05-20	2014-10-15	コニカミノルタ株式会社	有機エレクトロルミネッセンス素子、表示装置及び照明装置
JP5568889B2 (ja)	2009-05-22	2014-08-13	コニカミノルタ株式会社	有機エレクトロルミネッセンス素子、表示装置、照明装置及び有機エレクトロルミネッセンス素子材料
JP5629980B2 (ja)	2009-05-22	2014-11-26	コニカミノルタ株式会社	有機エレクトロルミネッセンス素子、表示装置及び照明装置
JP5499519B2 (ja)	2009-05-27	2014-05-21	コニカミノルタ株式会社	有機エレクトロルミネッセンス素子、表示装置及び照明装置
JP2012528083A (ja)	2009-05-27	2012-11-12	コーベンハブンスウニベルシテト	Ｎｃａｍに結合する線維芽細胞増殖因子レセプター由来ペプチド
GB0910003D0 (en)	2009-06-11	2009-07-22	Univ Leuven Kath	Novel compounds for the treatment of neurodegenerative diseases
JP5600894B2 (ja)	2009-06-24	2014-10-08	コニカミノルタ株式会社	白色有機エレクトロルミネッセンス素子、表示装置及び照明装置
ES2639065T5 (es)	2009-06-25	2023-01-30	Alkermes Pharma Ireland Ltd	Compuestos heterocíclicos para el tratamiento de trastornos neurológicos y psicológicos
EP2450348B1 (en)	2009-06-30	2016-12-14	Zeon Corporation	Novel diarylamine compound, and anti-aging agent, polymer composition, crosslinked rubber product and molded article thereof, and method for producing diarylamine compound
JPWO2011007819A1 (ja)	2009-07-17	2012-12-27	塩野義製薬株式会社	ラクタムまたはベンゼンスルホンアミド化合物を含有する医薬
US8680077B2 (en)	2009-07-24	2014-03-25	Duke University	Prochelators useful for inhibiting metal-associated toxicity
FR2948568B1 (fr)	2009-07-30	2012-08-24	Sanofi Aventis	Formulation pharmaceutique
TWI468402B (zh)	2009-07-31	2015-01-11	必治妥美雅史谷比公司	降低β－類澱粉生成之化合物
SG178106A1 (en)	2009-08-05	2012-03-29	Versitech Ltd	Antiviral compounds and methods of making and using thereof
JP2012197231A (ja)	2009-08-06	2012-10-18	Oncotherapy Science Ltd	Ｔｔｋ阻害作用を有するピリジンおよびピリミジン誘導体
MX2012001653A (es)	2009-08-07	2012-06-19	Hoffmann La Roche	Derivado de aminopirazol.
WO2011018894A1 (en)	2009-08-10	2011-02-17	Raqualia Pharma Inc.	Pyrrolopyrimidine derivatives as potassium channel modulators
US9085560B2 (en)	2009-08-17	2015-07-21	Intellikine, Inc.	Heterocyclic compounds and uses thereof
JP5577650B2 (ja)	2009-08-24	2014-08-27	コニカミノルタ株式会社	有機エレクトロルミネッセンス素子、有機エレクトロルミネッセンス素子材料、表示装置及び照明装置
KR101184115B1 (ko)	2009-08-31	2012-09-18	일동제약주식회사	신규 펩티드 데포르밀라제 저해제 화합물 및 그 제조방법
CN102656163B (zh)	2009-09-03	2016-01-13	拜奥埃内杰尼克斯公司	抑制pask的杂环化合物
CA2772790C (en)	2009-09-04	2017-06-27	Benjamin Bader	Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
WO2011031740A1 (en)	2009-09-09	2011-03-17	Achaogen, Inc.	Antibacterial fluoroquinolone analogs
US9481675B2 (en)	2009-09-11	2016-11-01	Merck Sharp & Dohme Corp.	Gyrase inhibitors
WO2011035376A1 (en)	2009-09-24	2011-03-31	Romar Engineering Pty Ltd	A mould or mould core and a method of manufacturing a mould or mould core
US8426438B2 (en)	2009-10-01	2013-04-23	Merck Sharp & Dohme Corp.	Heterocyclic-fused pyrazolo[4,3-c]pyridin-3-one M1 receptor positive allosteric modulators
US8466155B2 (en)	2009-10-02	2013-06-18	Boehringer Ingelheim International Gmbh	Pyrimidines
GB0917571D0 (en)	2009-10-07	2009-11-25	Karobio Ab	Novel estrogen receptor ligands
EP2308866A1 (de)	2009-10-09	2011-04-13	Bayer CropScience AG	Phenylpyri(mi)dinylpyrazole und ihre Verwendung als Fungizide
FR2951172B1 (fr)	2009-10-13	2014-09-26	Pf Medicament	Derives pyrazolopyridines en tant qu'agent anticancereux
EP2491033A4 (en)	2009-10-20	2013-03-13	Eiger Biopharmaceuticals Inc	AZAINDAZOLES FOR THE TREATMENT OF FLAVIVIRIDAE VIRUS INFECTION
KR20110043270A (ko)	2009-10-21	2011-04-27	(주)씨에스엘쏠라	유기발광화합물 및 이를 구비한 유기발광소자
ES2644286T3 (es)	2009-10-22	2017-11-28	Gilead Sciences, Inc.	Derivados de purina o deazapurina útiles para el tratamiento de (entre otros) infecciones víricas
WO2011050245A1 (en)	2009-10-23	2011-04-28	Yangbo Feng	Bicyclic heteroaryls as kinase inhibitors
MY177695A (en)	2009-10-26	2020-09-23	Signal Pharm Llc	Methods of synthesis and purification of heteroaryl compounds
EP2493864B1 (en)	2009-10-30	2014-10-01	Novartis AG	N-oxide of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea
KR20110049217A (ko)	2009-11-04	2011-05-12	다우어드밴스드디스플레이머티리얼 유한회사	신규한 유기 발광 화합물 및 이를 채용하고 있는 유기 전계 발광 소자
GB0919432D0 (en)	2009-11-05	2009-12-23	Glaxosmithkline Llc	Use
JP2013510166A (ja)	2009-11-06	2013-03-21	プレキシコンインコーポレーテッド	キナーゼ調節のための化合物、方法およびその適用
NZ599041A (en)	2009-11-13	2014-05-30	Genosco	Kinase inhibitors
BR112012011792A2 (pt)	2009-11-18	2015-10-13	Plexxikon Inc	"compostos e métodos para modulação de quinases, e indicações para os mesmos"
JP2013032290A (ja)	2009-11-20	2013-02-14	Dainippon Sumitomo Pharma Co Ltd	新規縮合ピリミジン誘導体
US20120232073A1 (en)	2009-11-23	2012-09-13	Santhosh Francis Neelamkavil	Fused bicyclic pyrimidine derivatives and methods of use thereof
JP2013512251A (ja)	2009-11-24	2013-04-11	アンプリミューン、インコーポレーテッド	Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害
EP2332939A1 (en)	2009-11-26	2011-06-15	Æterna Zentaris GmbH	Novel Naphthyridine derivatives and the use thereof as kinase inhibitors
WO2011068899A1 (en)	2009-12-01	2011-06-09	Abbott Laboratories	Novel tricyclic compounds
JP2011116840A (ja)	2009-12-02	2011-06-16	Fujifilm Corp	顔料微粒子分散体、これを用いた光硬化性組成物及びカラーフィルタ
AR079257A1 (es)	2009-12-07	2012-01-04	Novartis Ag	Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
EA022790B1 (ru)	2009-12-17	2016-03-31	Мерк Шарп Энд Домэ Корп.	Аминопиримидины в качестве syk ингибиторов
WO2011075620A1 (en)	2009-12-18	2011-06-23	Novartis Ag	Method for treating haematological cancers
SG10201502073PA (en)	2009-12-22	2015-05-28	Vertex Pharma	Isoindolinone inhibitors of phosphatidylinositol 3-kinase
FR2954315B1 (fr)	2009-12-23	2012-02-24	Galderma Res & Dev	Nouveaux derives phenoliques, et leur utilisation pharmaceutique ou cosmetique
WO2011079231A1 (en)	2009-12-23	2011-06-30	Gatekeeper Pharmaceutical, Inc.	Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
FR2954317B1 (fr)	2009-12-23	2012-01-27	Galderma Res & Dev	Nouveaux derives phenoliques, et leur utilisation pharmaceutique ou cosmetique
US20130096115A1 (en)	2009-12-28	2013-04-18	Afraxis, Inc.	Methods for treating autism
AU2010343102B2 (en)	2009-12-29	2016-03-24	Dana-Farber Cancer Institute, Inc.	Type II Raf kinase inhibitors
EP2519523A1 (en)	2009-12-29	2012-11-07	Polyera Corporation	Thionated aromatic bisimides as organic semiconductors and devices incorporating them
WO2011080755A1 (en)	2009-12-29	2011-07-07	Advinus Therapeutics Private Limited	Fused nitrogen heterocyclic compounds, process of preparation and uses thereof
WO2011082266A2 (en)	2009-12-30	2011-07-07	Arqule, Inc.	Substituted heterocyclic compounds
BR112012016376A2 (pt)	2009-12-30	2019-09-24	Arqule Inc	compostos de pirrolo-aminopirimida substituída
WO2011082267A2 (en)	2009-12-30	2011-07-07	Arqule, Inc.	Substituted triazolo-pyrazine compounds
CN102115026A (zh)	2009-12-31	2011-07-06	清华大学	一维纳米结构、其制备方法及一维纳米结构作标记的方法
US20130022629A1 (en)	2010-01-04	2013-01-24	Sharpe Arlene H	Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof
AR079975A1 (es)	2010-01-06	2012-03-07	British Columbia Cancer Agency	Agentes terapeuticos derivados de bisfenol u metodos para su uso, composiciones farmaceuticas y uso de los mismos
KR101483215B1 (ko)	2010-01-29	2015-01-16	한미약품 주식회사	단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체
WO2011094890A1 (en)	2010-02-02	2011-08-11	Argusina Inc.	Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
CA2789344A1 (en)	2010-02-15	2011-08-18	Jeremy Earle Wulff	Synthesis of bicyclic compounds and method for their use as therapeutic agents
SA111320200B1 (ar)	2010-02-17	2014-02-16	ديبيوفارم اس ايه	مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة
CA2789711C (en)	2010-02-17	2014-08-05	Amgen Inc.	Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain
WO2011103460A1 (en)	2010-02-18	2011-08-25	Medivation Technologies, Inc.	Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]ondole derivatives and methods of use
CN102782101B (zh)	2010-02-18	2015-10-07	Ntn株式会社	增稠剂、润滑脂及它们的制造方法以及润滑脂封入轴承
EP2536410B1 (en)	2010-02-18	2015-09-23	Merck Sharp & Dohme Corp.	Substituted pyrimidine derivatives and their use in treating viral infections
UY33227A (es)	2010-02-19	2011-09-30	Novartis Ag	Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
US9403769B2 (en)	2010-02-22	2016-08-02	Advanced Cancer Therapeutics, Llc	Small molecule inhibitors of PFKFB3 and glycolytic flux and their methods of use as anti-cancer therapeutics
US8986858B2 (en)	2010-02-26	2015-03-24	Nippon Steel & Sumikin Chemical Co., Ltd.	Organic electroluminescent device
US20130045203A1 (en)	2010-03-02	2013-02-21	Emory University	Uses of Noscapine and Derivatives in Subjects Diagnosed with FAP
WO2011111880A1 (ko)	2010-03-08	2011-09-15	주식회사 메디젠텍	세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물
WO2011112687A2 (en)	2010-03-10	2011-09-15	Kalypsys, Inc.	Heterocyclic inhibitors of histamine receptors for the treatment of disease
EP2545052B1 (en)	2010-03-11	2014-11-12	Gilead Connecticut, Inc.	Imidazopyridines syk inhibitors
WO2011115725A2 (en)	2010-03-16	2011-09-22	Dana-Farber Cancer Institute, Inc.	Indazole compounds and their uses
RU2018100142A (ru)	2010-03-24	2019-02-20	Амитек Терапетикс Солюшинс, Инк.	Гетероциклические соединения, эффективные для ингибирования киназы
WO2011123493A1 (en)	2010-03-31	2011-10-06	Bristol-Myers Squibb Company	Substituted pyrrolotriazines as protein kinase inhibitors
CN102153551B (zh)	2010-04-02	2012-04-25	济南海乐医药技术开发有限公司	基于吲唑或氮杂吲唑的双芳基脲或硫脲类结构抗肿瘤药物
JP5724204B2 (ja)	2010-04-07	2015-05-27	コニカミノルタ株式会社	有機エレクトロルミネッセンス素子、表示装置、及び照明装置
US8618095B2 (en)	2010-04-13	2013-12-31	Rigel Pharmaceuticals, Inc.	2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses
US8741903B2 (en)	2010-04-16	2014-06-03	Novartis Ag	Organic compound for use in the treatment of hepatocellular cancer (HCC)
WO2011133750A1 (en)	2010-04-22	2011-10-27	Janssen Pharmaceutica Nv	Indazole compounds useful as ketohexokinase inhibitors
AR081331A1 (es)	2010-04-23	2012-08-08	Cytokinetics Inc	Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
WO2011133722A2 (en)	2010-04-23	2011-10-27	Kineta, Inc.	Anti-viral compounds
CN103025744A (zh)	2010-04-30	2013-04-03	百时美施贵宝公司	作为α-7烟碱乙酰胆碱受体配体前药的氮杂二环胺N-氧化物化合物
GB201007286D0 (en)	2010-04-30	2010-06-16	Astex Therapeutics Ltd	New compounds
US8759398B2 (en)	2010-05-03	2014-06-24	Biolink Life Sciences, Inc.	Phosphorus binder composition for treatment of hyperphosphatemia
US20130137709A1 (en)	2010-05-05	2013-05-30	Nathanael S. Gray	Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith
MX2012013068A (es)	2010-05-11	2013-03-05	Aveo Pharmaceuticals Inc	Anticuerpos anti - fgfr2.
WO2011141848A1 (en)	2010-05-11	2011-11-17	Pfizer Inc.	Morpholine compounds as mineralocorticoid receptor antagonists
TWI513694B (zh)	2010-05-11	2015-12-21	Amgen Inc	抑制間變性淋巴瘤激酶的嘧啶化合物
JP5993368B2 (ja)	2010-05-12	2016-09-14	スペクトラムファーマシューティカルズインコーポレイテッド	炭酸ランタン水酸化物、ランタンオキシカルボネートならびにその製造および使用方法
US8293738B2 (en)	2010-05-12	2012-10-23	Abbott Laboratories	Indazole inhibitors of kinase
GB201008134D0 (en)	2010-05-14	2010-06-30	Medical Res Council Technology	Compounds
WO2011147199A1 (en)	2010-05-28	2011-12-01	Versitech Limited	Compounds and methods for treating viral infections
WO2011147198A1 (en)	2010-05-28	2011-12-01	Versitech Limited	Compounds and methods for treatment of proliferative diseases
WO2011153553A2 (en)	2010-06-04	2011-12-08	The Regents Of The University Of California	Methods and compositions for kinase inhibition
HRP20160771T1 (hr)	2010-06-04	2016-09-23	F. Hoffmann - La Roche Ag	Derivati aminopirimidina kao modulatori za lrrk2
WO2011155983A1 (en)	2010-06-07	2011-12-15	Bikam Pharmaceuticals Inc.	Opsin-binding ligands, compositions and methods of use
TW201210597A (en)	2010-06-09	2012-03-16	Gilead Sciences Inc	Inhibitors of hepatitis C virus
US8299117B2 (en)	2010-06-16	2012-10-30	Metabolex Inc.	GPR120 receptor agonists and uses thereof
US9163087B2 (en)	2010-06-18	2015-10-20	The Brigham And Women's Hospital, Inc.	Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions
WO2011163330A1 (en)	2010-06-24	2011-12-29	Merck Sharp & Dohme Corp.	Novel heterocyclic compounds as erk inhibitors
US8907053B2 (en)	2010-06-25	2014-12-09	Aurigene Discovery Technologies Limited	Immunosuppression modulating compounds
US8683564B2 (en)	2010-06-27	2014-03-25	King Saud University	One-time password authentication with infinite nested hash claims
WO2012000103A1 (en)	2010-07-02	2012-01-05	University Health Network	Methods of targeting pten mutant diseases and compositions therefor
JP2013530199A (ja)	2010-07-06	2013-07-25	ノバルティスアーゲー	キナーゼ阻害剤として有用な環状エーテル化合物
FR2962437B1 (fr)	2010-07-06	2012-08-17	Sanofi Aventis	Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique
FR2962438B1 (fr)	2010-07-06	2012-08-17	Sanofi Aventis	Derives d'indolizines, procedes de preparation et application en therapeutique
DE102010031127A1 (de)	2010-07-08	2012-01-12	Endress + Hauser Flowtec Ag	Messaufnehmer eines thermischen Durchflussmessgeräts zur Ermittlung des Durchflusses eines Mediums durch ein Messrohr und Verfahren zu dessen Herstellung
JP5810157B2 (ja)	2010-07-09	2015-11-11	ザ・ウォルター・アンド・エリザ・ホール・インスティテュート・オブ・メディカル・リサーチ	プロテインキナーゼ阻害剤および処置の方法
WO2012009258A2 (en)	2010-07-13	2012-01-19	Edward Roberts	Peptidomimetic galanin receptor modulators
EP2595996A2 (en)	2010-07-14	2013-05-29	Merck Sharp & Dohme Corp.	Tricyclic compounds as allosteric modulators of metabotropic glutamate receptors
TW201206946A (en)	2010-07-15	2012-02-16	Bristol Myers Squibb Co	Compounds for the reduction of beta-amyloid production
US20130225581A1 (en)	2010-07-16	2013-08-29	Kyowa Hakko Kirin Co., Ltd	Nitrogen-containing aromatic heterocyclic derivative
WO2012008564A1 (ja)	2010-07-16	2012-01-19	協和発酵キリン株式会社	含窒素芳香族複素環誘導体
EP2598505B1 (en)	2010-07-28	2015-03-18	Bayer Intellectual Property GmbH	Substituted imidazo[1,2-b]pyridazines
EP2413140A1 (en)	2010-07-29	2012-02-01	Sanofi	Method for identifying a compound having an antiarrhythmic effect as well as uses relating thereto
WO2012015274A2 (ko)	2010-07-30	2012-02-02	롬엔드하스전재재로코리아유한회사	유기발광화합물을 발광재료로서 채용하고 있는 유기 전계 발광 소자
US8906943B2 (en)	2010-08-05	2014-12-09	John R. Cashman	Synthetic compounds and methods to decrease nicotine self-administration
US8883839B2 (en)	2010-08-13	2014-11-11	Abbott Laboratories	Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9051280B2 (en)	2010-08-13	2015-06-09	AbbVie Deutschland GmbH & Co. KG	Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
EP2608669B1 (en)	2010-08-23	2016-06-22	Merck Sharp & Dohme Corp.	NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
WO2012027239A1 (en)	2010-08-23	2012-03-01	Schering Corporation	NOVEL PYRAZOLO[1,5-a]PYRROLO[3,2-e]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
KR20180031823A (ko)	2010-09-01	2018-03-28	질레드 코네티컷 인코포레이티드	피리다지논, 그의 제조 방법 및 사용 방법
CA2809836C (en)	2010-09-01	2019-01-15	Gilead Connecticut, Inc.	Pyridinones/pyrazinones, method of making, and method of use thereof for the treatment of disorders mediated by bruton's tyrosine kinase
US8735390B2 (en)	2010-09-08	2014-05-27	Glaxosmithkline Intellectual Property Development Limited	Polymorphs and salts
WO2012032065A1 (en)	2010-09-08	2012-03-15	Glaxo Group Limited	Indazole derivatives for use in the treatment of influenza virus infection
AR082799A1 (es)	2010-09-08	2013-01-09	Ucb Pharma Sa	Derivados de quinolina y quinoxalina como inhibidores de quinasa
TWI541243B (zh)	2010-09-10	2016-07-11	拜耳知識產權公司	經取代咪唑并嗒
CN103238117A (zh)	2010-09-14	2013-08-07	保土谷化学工业株式会社	电荷控制剂和使用其的调色剂
CN102399220A (zh)	2010-09-15	2012-04-04	黄振华	三并环类PI3K和mTOR双重抑制剂
CN102399233B (zh)	2010-09-15	2014-08-13	山东轩竹医药科技有限公司	PI3K和mTOR双重抑制剂类化合物
WO2012036233A1 (ja)	2010-09-17	2012-03-22	塩野義製薬株式会社	メラニン凝集ホルモン受容体アンタゴニスト活性を有する縮合へテロ環誘導体
GB201015949D0 (en)	2010-09-22	2010-11-03	Medical Res Council Technology	Compounds
JO3062B1 (ar)	2010-10-05	2017-03-15	Lilly Co Eli	R)-(e)-2-(4-(2-(5-(1-(3، 5-داي كلورو بيريدين-4-يل)إيثوكسي)-1h-إندازول-3-يل)?ينيل)-1h-بيرازول-1-يل)إيثانول بلوري
US8937077B2 (en)	2010-10-22	2015-01-20	Merck Sharp & Dohme Corp.	Bicyclic diamines as janus kinase inhibitors
RS55135B1 (sr)	2010-10-25	2016-12-30	G1 Therapeutics Inc	Cdk inhibitori
JP2012092049A (ja)	2010-10-27	2012-05-17	Sumitomo Chemical Co Ltd	有害動物防除組成物及び有害動物の防除方法
EP2632466A4 (en)	2010-10-29	2014-03-19	Univ Emory	CHINAZOLINE DERIVATIVES, COMPOSITIONS THEREOF AND USES THEREOF
WO2012061337A1 (en)	2010-11-02	2012-05-10	Exelixis, Inc.	Fgfr2 modulators
BR112013010768A2 (pt)	2010-11-10	2016-07-12	Gruenenthal Gmbh	derivados de ureia e carboxamida substituídos por heteroaromáticos como ligantes dos receptores vaniloides
WO2012063207A1 (en)	2010-11-10	2012-05-18	Actelion Pharmaceuticals Ltd	Lactam derivatives useful as orexin receptor antagonists
JP2012116825A (ja)	2010-11-11	2012-06-21	Ehime Univ	アセンジイミド化合物の製造方法
KR101171232B1 (ko)	2010-11-15	2012-08-06	단국대학교 산학협력단	스파이로 화합물 및 이를 포함하는 유기전계 발광소자
WO2012065297A1 (en)	2010-11-16	2012-05-24	Impact Therapeutics, Inc.	3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF
WO2012068343A1 (en)	2010-11-17	2012-05-24	Amgen Inc.	Quinoline derivatives as pik3 inhibitors
WO2012066578A2 (en)	2010-11-18	2012-05-24	Kasina Laila Innova Pharmaceuticals Private Limited	Substituted 4-(selenophen-2(or 3)-ylamino)pyrimidine compounds and methods of use thereof
GB201020179D0 (en)	2010-11-29	2011-01-12	Astex Therapeutics Ltd	New compounds
JP2014500277A (ja)	2010-12-09	2014-01-09	アムジエン・インコーポレーテツド	Ｐｉｍ阻害剤としての二環式化合物
WO2012080729A2 (en)	2010-12-14	2012-06-21	Electrophoretics Limited	CASEIN KINASE 1δ (CK1δ) INHIBITORS
EP2655357B1 (en)	2010-12-20	2016-06-22	Merck Serono S.A.	Indazolyl triazole derivatives as irak inhibitors
CN102603628B (zh)	2010-12-22	2016-08-17	香港理工大学	作为抗癌试剂的喹啉衍生物
US8754114B2 (en)	2010-12-22	2014-06-17	Incyte Corporation	Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
EP2655323B1 (en)	2010-12-22	2017-12-20	Leo Laboratories Limited	Ingenol-3-acylates iii and ingenol-3-carbamates
BR112013015859A2 (pt)	2010-12-22	2018-11-21	Leo Laboratories Ltd	composto, uso de um composto, métodos de prevenção, tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica
EP2468258A1 (en)	2010-12-22	2012-06-27	LEK Pharmaceuticals d.d.	Process for the preparation of a pharmaceutical composition comprising a low soluble pharmaceutically active ingredient
WO2012087784A1 (en)	2010-12-23	2012-06-28	Amgen Inc.	Heterocyclic compounds and their uses
JP5691508B2 (ja)	2010-12-27	2015-04-01	Jnc株式会社	ジイミド化合物ならびにインクジェット用インクおよびその用途
KR101466150B1 (ko)	2010-12-31	2014-11-27	제일모직 주식회사	유기광전소자용 화합물 및 이를 포함하는 유기광전소자
WO2012093731A1 (ja)	2011-01-06	2012-07-12	Ｊｘ日鉱日石エネルギー株式会社	イミド化合物及びその製造方法、グリース用増ちょう剤並びにグリース組成物
US8362023B2 (en)	2011-01-19	2013-01-29	Hoffmann-La Roche Inc.	Pyrazolo pyrimidines
FR2970967B1 (fr)	2011-01-27	2013-02-15	Pf Medicament	Derives de type azaindazole ou diazaindazole comme medicament
EP2487159A1 (en)	2011-02-11	2012-08-15	MSD Oss B.V.	RorgammaT inhibitors
WO2012112965A1 (en)	2011-02-18	2012-08-23	Medivation Technologies, Inc.	Compounds and methods of treating diabetes
US9127000B2 (en)	2011-02-23	2015-09-08	Intellikine, LLC.	Heterocyclic compounds and uses thereof
TWI532742B (zh)	2011-02-28	2016-05-11	艾伯維有限公司	激酶之三環抑制劑
CA2829988A1 (en)	2011-03-17	2012-09-20	Novartis Ag	Fgfr and ligands thereof as biomarkers for breast cancer in hr positive subjects
EP2688887B1 (en)	2011-03-23	2015-05-13	Amgen Inc.	Fused tricyclic dual inhibitors of cdk 4/6 and flt3
ITPD20110091A1 (it)	2011-03-24	2012-09-25	Univ Padova	Inibitori multitirosinchinasi utili per le patologie correlate: modelli farmacoforici, composti identificati tramite questi modelli, metodi per la loro preparazione, la loro formulazione e il loro impiego terapeutico.
MX351165B (es)	2011-03-25	2017-10-04	Abbvie Inc	Antagonistas de trpv1.
CN103596983B (zh)	2011-04-07	2016-10-26	霍夫曼-拉罗奇有限公司	抗fgfr4抗体及使用方法
FR2974088A1 (fr)	2011-04-12	2012-10-19	Pf Medicament	Composes pyrazolo[3,4-b]pyridines tri- et tetracycliques comme agent anticancereux
EA030462B1 (ru)	2011-05-16	2018-08-31	Дженентек, Инк.	Агонисты fgfr1 и способы их применения
US9376438B2 (en)	2011-05-17	2016-06-28	Principia Biopharma, Inc.	Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
CA2836203A1 (en)	2011-05-17	2012-11-22	Bayer Intellectual Property Gmbh	Amino-substituted imidazopyridazines as mknk1 kinase inhibitors
WO2012158994A1 (en)	2011-05-19	2012-11-22	Novartis Ag	4-amino-5-fluoro-3- [6- (4 -methylpiperazin- 1 - yl) - 1h - benzimidazol - 2 - yl] - 1h - quinoli n-2-one for use in the treatment of adenoid cystic carcinoma
CA2837630A1 (en)	2011-06-01	2012-12-06	Knut Eis	Substituted aminoimidazopyridazines
TW201316991A (zh)	2011-06-03	2013-05-01	Millennium Pharm Inc	Ｍｅｋ抑制劑與奧諾拉（ａｕｒｏｒａ）ａ激酶選擇性抑制劑之組合
CN103619989B (zh)	2011-06-13	2016-09-14	株式会社Lg化学	新的化合物以及使用其的有机电子器件
JP5944497B2 (ja)	2011-06-22	2016-07-05	バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＧｍｂＨ	ヘテロシクリルアミノイミダゾピリダジン
US8846656B2 (en)	2011-07-22	2014-09-30	Novartis Ag	Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
MY176647A (en)	2011-08-12	2020-08-19	Nissan Chemical Ind Ltd	Substituted pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidines and jak inhibitors comprising the same
WO2013024002A1 (en)	2011-08-12	2013-02-21	F. Hoffmann-La Roche Ag	PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE
JP2013049251A (ja)	2011-08-31	2013-03-14	Fujifilm Corp	レーザー彫刻用レリーフ印刷版原版、並びに、レリーフ印刷版及びその製版方法
WO2013033981A1 (zh)	2011-09-06	2013-03-14	江苏先声药物研究有限公司	一类2,7-萘啶衍生物及其制备方法和应用
EP2755482B1 (en)	2011-09-15	2016-06-01	Merck Sharp & Dohme Corp.	Combination of mk-1775 and mk-8776 for treating cancer
WO2013041634A1 (en)	2011-09-23	2013-03-28	Bayer Intellectual Property Gmbh	Substituted imidazopyridazines
US9376435B2 (en)	2011-09-23	2016-06-28	Jawaharlal Nehru Centre For Advanced Scientific Research	Chromophores for the detection of volatile organic compounds
CN103842364A (zh)	2011-09-30	2014-06-04	奇尼塔公司	抗病毒化合物
UA111382C2 (uk)	2011-10-10	2016-04-25	Оріон Корпорейшн	Інгібітори протеїнкінази
CA2850394C (en)	2011-10-12	2019-05-21	University Health Network	Indazole compounds as kinase inhibitors and method of treating cancer with same
KR101897044B1 (ko)	2011-10-20	2018-10-23	에스에프씨 주식회사	유기금속 화합물 및 이를 포함하는 유기전계발광소자
WO2013063003A1 (en)	2011-10-28	2013-05-02	Novartis Ag	Method of treating gastrointestinal stromal tumors
BR112014009993A2 (pt)	2011-10-28	2017-04-25	Novartis Ag	método para o tratamento de tumores do estroma gastrointestinal
WO2013088191A1 (en)	2011-12-12	2013-06-20	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3
JP6014163B2 (ja)	2011-12-13	2016-10-25	エコラボユーエスエーインコーポレイティド	濃縮物品洗浄組成物及び方法
FR2985257B1 (fr)	2011-12-28	2014-02-14	Sanofi Sa	Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique
FR2985258A1 (fr)	2011-12-28	2013-07-05	Sanofi Sa	Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique
US10026905B2 (en)	2012-01-18	2018-07-17	Duk San Neolux Co., Ltd.	Compound, organic electric element using the same, and an electronic device thereof
WO2013109027A1 (ko)	2012-01-18	2013-07-25	덕산하이메탈(주)	화합물, 이를 이용한 유기전기소자 및 그 전자 장치
PT2657233E (pt)	2012-01-19	2014-10-24	Taiho Pharmaceutical Co Ltd	Composto de alcinil-benzeno substituído nas posições 3 e 5 e um seu sal
CN104136439B (zh)	2012-02-23	2017-01-18	拜耳知识产权有限责任公司	取代的苯并噻吩基‑吡咯并三嗪及其用途
JP2013179181A (ja)	2012-02-28	2013-09-09	Sumitomo Chemical Co Ltd	有機光電変換素子
US9428499B2 (en)	2012-03-14	2016-08-30	Lupin Limited	Heterocyclyl compounds as MEK inhibitors
KR102126092B1 (ko)	2012-03-30	2020-06-24	노파르티스 아게	저인산혈증성 장애의 치료에 사용하기 위한 fgfr 억제제
JP5120580B1 (ja)	2012-05-14	2013-01-16	Ｊｓｒ株式会社	液晶配向剤
WO2013175468A2 (en)	2012-05-20	2013-11-28	Tel Hashomer Medical Research Infrastructure And Services Ltd.	Prosthetic mitral valve
NZ743274A (en)	2012-06-13	2019-07-26	Incyte Holdings Corp	Substituted tricyclic compounds as fgfr inhibitors
CA2878412A1 (en)	2012-07-11	2014-01-16	Blueprint Medicines Corporation	Inhibitors of the fibroblast growth factor receptor
WO2014011284A1 (en)	2012-07-11	2014-01-16	Novartis Ag	Method of treating gastrointestinal stromal tumors
WO2014019186A1 (en)	2012-08-02	2014-02-06	Merck Sharp & Dohme Corp.	Antidiabetic tricyclic compounds
MX2015001500A (es)	2012-08-02	2015-04-08	Merck Sharp & Dohme	Compuestos antidiabeticos triciclicos.
KR101985259B1 (ko)	2012-08-10	2019-06-03	제이에스알 가부시끼가이샤	액정 배향제 및 화합물
US9388185B2 (en)	2012-08-10	2016-07-12	Incyte Holdings Corporation	Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
WO2014044846A1 (en)	2012-09-24	2014-03-27	Evotec (Uk) Ltd.	3-(aryl- or heteroaryl-amino)-7-(3,5-dimethoxyphenyl)isoquinoline derivatives as fgfr inhibitors useful for the treatment of proliferative disorders or dysplasia
WO2014048878A1 (en)	2012-09-26	2014-04-03	Evotec (Uk) Ltd.	Phenyl- or pyridyl- pyrrolo[2,3b]pyrazine derivatives useful in the treatment or prevention of proliferative disorders or dysplasia
WO2014062454A1 (en)	2012-10-15	2014-04-24	Merck Sharp & Dohme Corp.	Compositions and methods for treating cancer
KR102000211B1 (ko)	2012-10-29	2019-09-30	삼성디스플레이 주식회사	유기금속 화합물 및 이를 포함한 유기 발광 소자
US20140148548A1 (en)	2012-11-28	2014-05-29	Central Glass Company, Limited	Fluorine-Containing Polymerizable Monomer And Polymer Compound Using Same
AU2013352568B2 (en)	2012-11-28	2019-09-19	Merck Sharp & Dohme Llc	Compositions and methods for treating cancer
WO2014089913A1 (zh)	2012-12-12	2014-06-19	山东亨利医药科技有限责任公司	作为酪氨酸激酶抑制剂的并环化合物
US9266892B2 (en)	2012-12-19	2016-02-23	Incyte Holdings Corporation	Fused pyrazoles as FGFR inhibitors
TWI629266B (zh)	2012-12-28	2018-07-11	藍印藥品公司	纖維母細胞生長因子受體之抑制劑
WO2014105849A1 (en)	2012-12-28	2014-07-03	Xoma (Us) Llc	Antibodies specific for fgfr4 and methods of use
KR102030587B1 (ko)	2013-01-09	2019-10-10	에스에프씨주식회사	두 개의 나프틸기를 포함하는 비대칭 안트라센 유도체 및 이를 포함하는 유기 발광 소자
CN103588771B (zh)	2013-01-15	2016-01-27	苏州云轩医药科技有限公司	具有刺猬通路拮抗剂活性的嘧啶类抗肿瘤化合物
US9695178B2 (en)	2013-01-15	2017-07-04	Suzhou Kintor Pharmaceuticals, Inc.	6-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-D]pyrimidine analogs as hedgehog pathway signaling inhibitors and therapeutic applications thereof
KR101456626B1 (ko)	2013-02-01	2014-11-03	대영이앤비 주식회사	냉장고 부압 방지 장치
JP6311093B2 (ja)	2013-03-07	2018-04-18	国立大学法人九州大学	超分子複合体、発光体、および有機化合物検出用のセンサー素子
WO2014138485A1 (en)	2013-03-08	2014-09-12	Irm Llc	Ex vivo production of platelets from hematopoietic stem cells and the product thereof
US20140371238A1 (en)	2013-03-13	2014-12-18	Flatley Discovery Lab	Compounds and methods for the treatment of cystic fibrosis
US9498532B2 (en)	2013-03-13	2016-11-22	Novartis Ag	Antibody drug conjugates
US9163019B2 (en)	2013-03-14	2015-10-20	AbbVie Deutschland GmbH & Co. KG	Inhibitor compounds of phosphodiesterase type 10A
CA2907243C (en)	2013-03-15	2021-12-28	Celgene Avilomics Research, Inc.	Substituted dihydropyrimidopyrimidinone compounds and pharmaceutical compositions thereof use fgfr4 inhibitor
AR095464A1 (es)	2013-03-15	2015-10-21	Celgene Avilomics Res Inc	Compuestos de heteroarilo y usos de los mismos
BR112015022191A8 (pt)	2013-03-15	2018-01-23	Celgene Avilomics Res Inc	compostos heteroarila e usos dos mesmos
EP2970231A1 (en)	2013-03-15	2016-01-20	Blueprint Medicines Corporation	Piperazine derivatives and their use as kit modulators
TWI628176B (zh)	2013-04-04	2018-07-01	奧利安公司	蛋白質激酶抑制劑
KR101573611B1 (ko)	2013-04-17	2015-12-01	주식회사 엘지화학	플러렌 유도체, 이를 이용한 유기 태양 전지 및 이의 제조 방법
LT2986610T (lt)	2013-04-19	2018-04-10	Incyte Holdings Corporation	Bicikliniai heterociklai, kaip fgfr inhibitoriai
WO2014170063A1 (en)	2013-04-19	2014-10-23	Covagen Ag	Novel bispecific binding molecules with antitumoral activity
GB201307577D0 (en)	2013-04-26	2013-06-12	Astex Therapeutics Ltd	New compounds
US9630963B2 (en)	2013-05-09	2017-04-25	Principia Biopharma, Inc.	Quinolone derivatives as fibroblast growth factor inhibitors
EP3007694B1 (en)	2013-06-14	2018-07-18	Sanofi	Pyrazolopyridine derivatives for use in the treatment of bladder cancer
EP3013797B1 (en)	2013-06-28	2018-01-03	BeiGene, Ltd.	Fused tricyclic amide compounds as multiple kinase inhibitors
CN105452223B (zh)	2013-06-28	2018-10-02	百济神州有限公司	作为Raf激酶和/或Raf激酶二聚体抑制剂的稠合三环脲类化合物
JP6677637B2 (ja)	2013-07-02	2020-04-08	シンジェンタパーティシペーションズアーゲー	有害生物防除的に活性な、硫黄含有置換基を有する二環式または三環式複素環
US9783504B2 (en)	2013-07-09	2017-10-10	Dana-Farber Cancer Institute, Inc.	Kinase inhibitors for the treatment of disease
JP6018547B2 (ja)	2013-07-09	2016-11-02	大成ロテック株式会社	舗装機械
AU2014287016B2 (en)	2013-07-11	2018-11-01	Acea Biosciences Inc.	Pyrimidine derivatives as kinase inhibitors
AR097455A1 (es)	2013-08-28	2016-03-16	Astellas Pharma Inc	Composición farmacéutica que contiene compuesto de pirimidina como un ingrediente activo
RS57444B1 (sr)	2013-10-18	2018-09-28	Eisai R&D Man Co Ltd	Pirimidin fgfr4 inhibitori
PT3395814T (pt)	2013-10-25	2022-07-27	Blueprint Medicines Corp	Inibidores do recetor do fator de crescimento de fibroblastos
MX367723B (es)	2013-10-25	2019-09-03	Novartis Ag	Compuestos de anillos fusionados bicíclicos derivados de piridilo como inhibidores de fgfr4.
FR3012330B1 (fr)	2013-10-29	2015-10-23	Oreal	Composition biphase comprenant un ester d'acide gras et de sucre ou un alkylpolyglucoside liquide, de hlb < 8, et un alcane ramifie en c8-c18
WO2015066452A2 (en)	2013-11-01	2015-05-07	Foundation Medicine, Inc.	Methods of treating pediatric cancers
WO2015108992A1 (en)	2014-01-15	2015-07-23	Blueprint Medicines Corporation	Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
WO2016026445A1 (zh)	2014-08-19	2016-02-25	上海海和药物研究开发有限公司	作为fgfr激酶抑制剂的吲唑类化合物及其制备和应用
CN104262330B (zh)	2014-08-27	2016-09-14	广东东阳光药业有限公司	一种脲取代联苯类化合物及其组合物及用途
KR20170049604A (ko)	2014-09-19	2017-05-10	바이엘 파마 악티엔게젤샤프트	Bub1 억제제로서의 벤질 치환된 인다졸
US10851105B2 (en)	2014-10-22	2020-12-01	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
US20160115164A1 (en)	2014-10-22	2016-04-28	Incyte Corporation	Bicyclic heterocycles as fgfr4 inhibitors
CN113004278B (zh)	2015-02-20	2023-07-21	因赛特控股公司	作为fgfr抑制剂的双环杂环
MA41551A (fr)	2015-02-20	2017-12-26	Incyte Corp	Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US9701650B2 (en)	2015-02-20	2017-07-11	Oregon Health & Science University	Derivatives of sobetirome
US9580423B2 (en)	2015-02-20	2017-02-28	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
EP4512394A2 (en)	2015-06-03	2025-02-26	Triastek, Inc.	Dosage forms and use thereof
PT3322701T (pt)	2015-07-15	2019-06-28	Hoffmann La Roche	Derivados de etinilo enquanto moduladores do recetor metabotrópico de glutamato
MY189596A (en)	2015-07-15	2022-02-18	Immatics Biotechnologies Gmbh	A novel peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
CA2991984A1 (en)	2015-07-15	2017-01-19	Protagonist Therapeutics, Inc.	Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
AU2016294421B2 (en)	2015-07-15	2018-10-18	Cabot Corporation	Methods of making an elastomer composite reinforced with silica and products containing same
FI3981792T3 (fi)	2015-07-30	2024-09-23	Macrogenics Inc	Pd-1:tä sitovia molekyylejä ja niiden käyttömenetelmiä
WO2017023988A1 (en)	2015-08-03	2017-02-09	Samumed, Llc.	3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017024025A1 (en)	2015-08-03	2017-02-09	Sunil Kumar Kc	3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10329309B2 (en)	2015-08-03	2019-06-25	Samumed, Llc	3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10231956B2 (en)	2015-08-03	2019-03-19	Samumed, Llc	3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017024004A1 (en)	2015-08-03	2017-02-09	Samumed, Llc.	3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10392383B2 (en)	2015-08-03	2019-08-27	Samumed, Llc	3-(1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017023972A1 (en)	2015-08-03	2017-02-09	Samumed, Llc.	3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
EP3337787B1 (en)	2015-08-20	2021-03-03	JS InnoPharm (Shanghai) Ltd.	1h-pyrazolo[3,4-b]pyridine, 1h-thieno[2,3-c]pyrazole and 1h-indazole carboxamide derivatives and related compounds as extracellular signal-regulated kinases (erk) inhibitors for treating cancer
EP3356349A1 (en)	2015-09-28	2018-08-08	Araxes Pharma LLC	Inhibitors of kras g12c mutant proteins
TW201718581A (zh)	2015-10-19	2017-06-01	英塞特公司	作為免疫調節劑之雜環化合物
US10208024B2 (en)	2015-10-23	2019-02-19	Array Biopharma Inc.	2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases
TWI763641B (zh)	2015-11-19	2022-05-11	美商英塞特公司	作為免疫調節劑之雜環化合物
US20170174671A1 (en)	2015-12-17	2017-06-22	Incyte Corporation	Heterocyclic compounds as immunomodulators
UA126113C2 (uk)	2015-12-22	2022-08-17	Інсайт Корпорейшн	Гетероциклічні сполуки як імуномодулятори
MA44860A (fr)	2016-05-06	2019-03-13	Incyte Holdings Corp	Composés hétérocycliques utilisés comme immunomodulateurs
US20170342060A1 (en)	2016-05-26	2017-11-30	Incyte Corporation	Heterocyclic compounds as immunomodulators
HUE060256T2 (hu)	2016-06-20	2023-02-28	Incyte Corp	Heterociklusos vegyületek mint immunmodulátorok
TW201803871A (zh)	2016-06-24	2018-02-01	英塞特公司	作為ＰＩ３Ｋ-γ抑制劑之雜環化合物
EP3484866B1 (en)	2016-07-14	2022-09-07	Incyte Corporation	Heterocyclic compounds as immunomodulators
EP3504198B1 (en)	2016-08-29	2023-01-25	Incyte Corporation	Heterocyclic compounds as immunomodulators
US10647693B2 (en)	2016-08-30	2020-05-12	North & South Brother Pharmacy Investment Company Limited	Inhibitors of influenza virus replication, application methods and uses thereof
WO2018049214A1 (en)	2016-09-09	2018-03-15	Incyte Corporation	Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
RU2019107667A (ru)	2016-10-05	2020-11-06	РЕКЬЮРИУМ АйПи ХОЛДИНГС, ЛЛС	Спироциклические соединения
KR101755556B1 (ko)	2016-11-18	2017-07-07	주식회사 케마스	육산화사비소의 결정다형을 포함하는 뇌암 예방 또는 치료용 약학 조성물 및 이의 제조방법
KR101834366B1 (ko)	2016-11-21	2018-03-05	주식회사 케마스	육산화사비소의 결정다형을 포함하는 유방암 예방 또는 치료용 약학 조성물 및 이의 제조방법
KR101844049B1 (ko)	2016-12-05	2018-03-30	주식회사 케마스	육산화사비소의 결정다형을 포함하는 간암 예방 또는 치료용 약학 조성물
KR101844050B1 (ko)	2016-12-09	2018-05-14	주식회사 케마스	육산화사비소의 결정다형을 포함하는 암 예방 또는 치료용 약학 조성물
TW201835049A (zh)	2016-12-22	2018-10-01	美商英塞特公司	作為免疫調節劑之雜環化合物
ES2874756T3 (es)	2016-12-22	2021-11-05	Incyte Corp	Derivados de triazolo[1,5-A]piridina como inmunomoduladores
US20180179179A1 (en)	2016-12-22	2018-06-28	Incyte Corporation	Heterocyclic compounds as immunomodulators
WO2018119263A1 (en)	2016-12-22	2018-06-28	Incyte Corporation	Heterocyclic compounds derivatives as pd-l1 internalization inducers
UA126394C2 (uk)	2016-12-22	2022-09-28	Інсайт Корпорейшн	Похідні бензоксазолу як імуномодулятори
CN116115764A (zh)	2016-12-22	2023-05-16	因赛特公司	四氢咪唑并[4,5-c]吡啶衍生物作为pd-l1内在化诱导剂
AR111960A1 (es)	2017-05-26	2019-09-04	Incyte Corp	Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
WO2018234354A1 (en)	2017-06-20	2018-12-27	Grünenthal GmbH	NOVEL SUBSTITUTED 3-INDOLE AND 3-INDAZOLE COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS
EP3672973A4 (en)	2017-08-22	2021-05-26	JS Innopharm (Shanghai) Ltd.	HETEROCYCLIC COMPOUNDS USED AS KINASE INHIBITORS, COMPOSITIONS INCLUDING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF
WO2019079369A1 (en)	2017-10-19	2019-04-25	Effector Therapeutics, Inc.	BENZIMIDAZOLE INDOLE INHIBITORS OF MNK1 AND MNK2
PT3717471T (pt)	2017-12-02	2022-03-08	Galapagos Nv	Novos compostos e composições farmacêuticas dos mesmos para o tratamento de doenças
HRP20250421T1 (hr)	2018-03-30	2025-06-06	Incyte Corporation	Heterociklički spojevi kao imunomodulatori
AU2019262579B2 (en)	2018-05-04	2024-09-12	Incyte Corporation	Salts of an FGFR inhibitor
PL3788047T3 (pl)	2018-05-04	2025-04-14	Incyte Corporation	Stałe postacie inhibitora fgfr i sposoby ich otrzymywania
IL278605B2 (en)	2018-05-11	2025-03-01	Incyte Corp	Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators
KR20210075071A (ko)	2018-08-14	2021-06-22	오스테오큐씨 인코포레이티드	피롤로-디피리딘 화합물
EP3846904B1 (en)	2018-09-07	2023-05-31	Merck Patent GmbH	5-morpholin-4-yl-pyrazolo[4,3-b]pyridine derivatives
WO2020081898A1 (en)	2018-10-20	2020-04-23	The Johns Hopkins University	Non-invasive urinary biomarkers for the detection of urothelial carcinoma of the bladder
EP3898626A1 (en)	2018-12-19	2021-10-27	Array Biopharma, Inc.	Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
CN113474337A (zh)	2018-12-19	2021-10-01	奥瑞生物药品公司	作为fgfr抑制剂用于治疗癌症的7-((3，5-二甲氧基苯基)氨基)喹喔啉衍生物
WO2020185532A1 (en)	2019-03-08	2020-09-17	Incyte Corporation	Methods of treating cancer with an fgfr inhibitor
US11591329B2 (en)	2019-07-09	2023-02-28	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
WO2021067374A1 (en)	2019-10-01	2021-04-08	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
CN115835908A (zh)	2019-10-14	2023-03-21	因赛特公司	作为fgfr抑制剂的双环杂环
US11566028B2 (en)	2019-10-16	2023-01-31	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
CA3163875A1 (en)	2019-12-04	2021-06-10	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors
WO2021113462A1 (en)	2019-12-04	2021-06-10	Incyte Corporation	Derivatives of an fgfr inhibitor
WO2021146424A1 (en)	2020-01-15	2021-07-22	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
CA3215903A1 (en)	2021-04-12	2022-10-20	Incyte Corporation	Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent

2013
- 2013-06-12 NZ NZ743274A patent/NZ743274A/en unknown
- 2013-06-12 CA CA2876689A patent/CA2876689C/en active Active
- 2013-06-12 SM SM20170146T patent/SMT201700146T1/it unknown
- 2013-06-12 SI SI201331298T patent/SI3176170T1/sl unknown
- 2013-06-12 LT LTEP18198112.7T patent/LT3495367T/lt unknown
- 2013-06-12 PH PH1/2019/502809A patent/PH12019502809B1/en unknown
- 2013-06-12 PT PT16203866T patent/PT3176170T/pt unknown
- 2013-06-12 UA UAA201801562A patent/UA125503C2/uk unknown
- 2013-06-12 SG SG10201610416TA patent/SG10201610416TA/en unknown
- 2013-06-12 AR ARP130102068A patent/AR091424A1/es active IP Right Grant
- 2013-06-12 DK DK18198112.7T patent/DK3495367T3/da active
- 2013-06-12 AU AU2013287176A patent/AU2013287176C1/en active Active
- 2013-06-12 EP EP18198112.7A patent/EP3495367B1/en active Active
- 2013-06-12 PL PL16203866T patent/PL3176170T3/pl unknown
- 2013-06-12 NZ NZ702747A patent/NZ702747A/en unknown
- 2013-06-12 SM SM20190040T patent/SMT201900040T1/it unknown
- 2013-06-12 LT LTEP13783125.1T patent/LT2861595T/lt unknown
- 2013-06-12 EP EP13783125.1A patent/EP2861595B9/en active Active
- 2013-06-12 RS RS20201398A patent/RS61089B1/sr unknown
- 2013-06-12 MY MYPI2014003396A patent/MY171375A/en unknown
- 2013-06-12 ES ES18198112T patent/ES2832497T3/es active Active
- 2013-06-12 UA UAA201500191A patent/UA117347C2/uk unknown
- 2013-06-12 EA EA201590005A patent/EA036592B1/ru unknown
- 2013-06-12 HU HUE16203866A patent/HUE042374T2/hu unknown
- 2013-06-12 CN CN201380041027.9A patent/CN104507943B/zh active Active
- 2013-06-12 PL PL13783125T patent/PL2861595T3/pl unknown
- 2013-06-12 PE PE2019000866A patent/PE20190736A1/es unknown
- 2013-06-12 MX MX2014015192A patent/MX359293B/es active IP Right Grant
- 2013-06-12 HU HUE18198112A patent/HUE052195T2/hu unknown
- 2013-06-12 ME MEP-2019-2A patent/ME03300B/me unknown
- 2013-06-12 RS RS20190048A patent/RS58514B1/sr unknown
- 2013-06-12 SI SI201331805T patent/SI3495367T1/sl unknown
- 2013-06-12 ME MEP-2017-67A patent/ME02651B/me unknown
- 2013-06-12 MX MX2018006473A patent/MX389376B/es unknown
- 2013-06-12 LT LTEP16203866.5T patent/LT3176170T/lt unknown
- 2013-06-12 PL PL18198112T patent/PL3495367T3/pl unknown
- 2013-06-12 KR KR1020157000701A patent/KR102140426B1/ko active Active
- 2013-06-12 SI SI201330583A patent/SI2861595T1/sl unknown
- 2013-06-12 IL IL289834A patent/IL289834B2/en unknown
- 2013-06-12 EP EP24164194.3A patent/EP4403216A3/en active Pending
- 2013-06-12 HR HRP20170430TT patent/HRP20170430T1/hr unknown
- 2013-06-12 WO PCT/US2013/045309 patent/WO2014007951A2/en active Application Filing
- 2013-06-12 ES ES16203866T patent/ES2704744T3/es active Active
- 2013-06-12 CA CA3149881A patent/CA3149881A1/en active Pending
- 2013-06-12 SG SG11201408238WA patent/SG11201408238WA/en unknown
- 2013-06-12 DK DK16203866.5T patent/DK3176170T3/en active
- 2013-06-12 DK DK13783125.1T patent/DK2861595T5/en active
- 2013-06-12 JP JP2015517376A patent/JP6301321B2/ja active Active
- 2013-06-12 CN CN201710874686.0A patent/CN107652289B/zh active Active
- 2013-06-12 HU HUE13783125A patent/HUE031916T2/en unknown
- 2013-06-12 ES ES20192679T patent/ES2984771T3/es active Active
- 2013-06-12 KR KR1020207021884A patent/KR102406771B1/ko active Active
- 2013-06-12 EP EP16203866.5A patent/EP3176170B1/en active Active
- 2013-06-12 EP EP20192679.7A patent/EP3822273B1/en active Active
- 2013-06-12 CN CN201710395346.XA patent/CN107383009B/zh active Active
- 2013-06-12 US US13/915,775 patent/US9611267B2/en active Active
- 2013-06-12 PE PE2014002433A patent/PE20150684A1/es active IP Right Grant
- 2013-06-12 BR BR112014030812-8A patent/BR112014030812B1/pt active IP Right Grant
- 2013-06-12 ES ES13783125T patent/ES2618003T3/es active Active
- 2013-06-12 KR KR1020227018808A patent/KR102556118B1/ko active Active
- 2013-06-12 PT PT181981127T patent/PT3495367T/pt unknown
- 2013-06-12 NZ NZ730134A patent/NZ730134A/en unknown
- 2013-06-12 SM SM20200673T patent/SMT202000673T1/it unknown
- 2013-06-12 RS RS20170276A patent/RS55908B1/sr unknown
- 2013-06-12 PT PT137831251T patent/PT2861595T/pt unknown
- 2013-06-13 TW TW109132389A patent/TWI769529B/zh active
- 2013-06-13 TW TW111107608A patent/TWI801156B/zh active
- 2013-06-13 TW TW102120946A patent/TWI706953B/zh active
2014
- 2014-12-04 IL IL236078A patent/IL236078B/en active IP Right Grant
- 2014-12-05 MY MYPI2018000373A patent/MY188363A/en unknown
- 2014-12-10 PH PH12014502772A patent/PH12014502772A1/en unknown
- 2014-12-10 MX MX2022000517A patent/MX2022000517A/es unknown
- 2014-12-10 CL CL2014003355A patent/CL2014003355A1/es unknown
- 2014-12-16 CO CO14275934A patent/CO7240375A2/es unknown
2017
- 2017-01-18 US US15/408,768 patent/US10131667B2/en active Active
- 2017-03-16 CY CY20171100335T patent/CY1118744T1/el unknown
- 2017-08-03 CL CL2017001984A patent/CL2017001984A1/es unknown
- 2017-08-21 JP JP2017158805A patent/JP6336665B2/ja active Active
2018
- 2018-01-17 IL IL256976A patent/IL256976B/en active IP Right Grant
- 2018-05-02 JP JP2018088682A patent/JP6545863B2/ja active Active
- 2018-10-05 US US16/152,827 patent/US20190127376A1/en not_active Abandoned
2019
- 2019-01-02 HR HRP20190007TT patent/HRP20190007T1/hr unknown
- 2019-01-07 AU AU2019200066A patent/AU2019200066B2/en active Active
- 2019-02-06 CY CY20191100164T patent/CY1121299T1/el unknown
- 2019-06-19 JP JP2019113954A patent/JP6711946B2/ja active Active
2020
- 2020-04-07 US US16/842,558 patent/US11053246B2/en active Active
- 2020-05-28 JP JP2020093529A patent/JP7200170B2/ja active Active
- 2020-08-02 IL IL276433A patent/IL276433B/en active IP Right Grant
- 2020-11-18 AU AU2020270520A patent/AU2020270520B2/en active Active
- 2020-12-08 HR HRP20201966TT patent/HRP20201966T1/hr unknown
- 2020-12-14 CY CY20201101183T patent/CY1123631T1/el unknown
2021
- 2021-04-25 IL IL282622A patent/IL282622B/en unknown
- 2021-06-02 US US17/337,027 patent/US11840534B2/en active Active
- 2021-09-09 HU HUS2100035C patent/HUS2100035I1/hu unknown
- 2021-09-09 NO NO2021034C patent/NO2021034I1/no unknown
- 2021-09-10 LU LU00222C patent/LUC00222I2/en unknown
- 2021-09-10 LT LTPA2021519C patent/LTC2861595I2/lt unknown
- 2021-09-10 CY CY2021026C patent/CY2021026I1/el unknown
- 2021-09-21 NL NL301131C patent/NL301131I2/nl unknown
2022
- 2022-12-01 EC ECSENADI202291792A patent/ECSP22091792A/es unknown
- 2022-12-21 AU AU2022291504A patent/AU2022291504B2/en active Active
- 2022-12-21 JP JP2022204466A patent/JP7392096B2/ja active Active
2023
- 2023-10-20 US US18/382,210 patent/US20240246974A1/en active Pending
- 2023-11-22 JP JP2023197898A patent/JP7646791B2/ja active Active
2024
- 2024-10-30 AU AU2024227763A patent/AU2024227763A1/en active Pending
2025
- 2025-03-05 JP JP2025034502A patent/JP2025084979A/ja active Pending

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US10813930B2 (en)	2010-12-22	2020-10-27	Incyte Corporation	Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
US11840534B2 (en)	2012-06-13	2023-12-12	Incyte Corporation	Substituted tricyclic compounds as FGFR inhibitors
US11053246B2 (en)	2012-06-13	2021-07-06	Incyte Corporation	Substituted tricyclic compounds as FGFR inhibitors
US10947230B2 (en)	2013-04-19	2021-03-16	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
US11530214B2 (en)	2013-04-19	2022-12-20	Incyte Holdings Corporation	Bicyclic heterocycles as FGFR inhibitors
US10851105B2 (en)	2014-10-22	2020-12-01	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
US11173162B2 (en)	2015-02-20	2021-11-16	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
US10632126B2 (en)	2015-02-20	2020-04-28	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
US11667635B2 (en)	2015-02-20	2023-06-06	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
US11014923B2 (en)	2015-02-20	2021-05-25	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
US10738048B2 (en)	2015-02-20	2020-08-11	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
US11472801B2 (en)	2017-05-26	2022-10-18	Incyte Corporation	Crystalline forms of a FGFR inhibitor and processes for preparing the same
US11174257B2 (en)	2018-05-04	2021-11-16	Incyte Corporation	Salts of an FGFR inhibitor
US11466004B2 (en)	2018-05-04	2022-10-11	Incyte Corporation	Solid forms of an FGFR inhibitor and processes for preparing the same
US12024517B2 (en)	2018-05-04	2024-07-02	Incyte Corporation	Salts of an FGFR inhibitor
US11628162B2 (en)	2019-03-08	2023-04-18	Incyte Corporation	Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en)	2019-07-09	2023-02-28	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
US12122767B2 (en)	2019-10-01	2024-10-22	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
US11607416B2 (en)	2019-10-14	2023-03-21	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
US12083124B2 (en)	2019-10-14	2024-09-10	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
US11566028B2 (en)	2019-10-16	2023-01-31	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
US11897891B2 (en)	2019-12-04	2024-02-13	Incyte Corporation	Tricyclic heterocycles as FGFR inhibitors
US12168660B2 (en)	2019-12-04	2024-12-17	Incyte Corporation	Derivatives of an FGFR inhibitor
US11407750B2 (en)	2019-12-04	2022-08-09	Incyte Corporation	Derivatives of an FGFR inhibitor
US12012409B2 (en)	2020-01-15	2024-06-18	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
US12065494B2 (en)	2021-04-12	2024-08-20	Incyte Corporation	Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent
US11939331B2 (en)	2021-06-09	2024-03-26	Incyte Corporation	Tricyclic heterocycles as FGFR inhibitors

Also Published As

Publication number	Publication date
NZ743274A (en)	2019-07-26
KR102556118B1 (ko)	2023-07-19
IL276433A (en)	2020-09-30
LTC2861595I2 (es)	2023-06-26
SI3495367T1 (sl)	2021-01-29
TW201402574A (zh)	2014-01-16
ES2832497T3 (es)	2021-06-10
EP3176170B1 (en)	2018-11-14
JP6711946B2 (ja)	2020-06-17
EP3822273B1 (en)	2024-04-10
AU2024227763A1 (en)	2025-01-02
AU2022291504A1 (en)	2023-02-02
ES2704744T3 (es)	2019-03-19
RS58514B1 (sr)	2019-04-30
RS61089B1 (sr)	2020-12-31
MY188363A (en)	2021-12-04
HRP20190007T1 (hr)	2019-04-05
JP6545863B2 (ja)	2019-07-17
TW202241898A (zh)	2022-11-01
CN104507943B (zh)	2017-11-21
ES2618003T8 (es)	2021-08-24
CN107652289A (zh)	2018-02-02
BR112014030812B1 (pt)	2022-11-08
NZ730134A (en)	2018-07-27
EP2861595A2 (en)	2015-04-22
LT3176170T (lt)	2019-04-25
PL2861595T3 (pl)	2017-06-30
EA201590005A1 (ru)	2015-05-29
HRP20201966T1 (hr)	2021-02-05
NL301131I2 (nl)	2021-10-25
SI2861595T1 (sl)	2017-04-26
IL236078A0 (en)	2015-02-01
AU2019200066A1 (en)	2019-01-24
CN107652289B (zh)	2020-07-21
TWI769529B (zh)	2022-07-01
DK2861595T5 (en)	2018-01-15
PH12014502772B1 (en)	2015-02-02
CY2021026I2 (el)	2021-12-31
ES2618003T9 (es)	2018-03-02
CA2876689C (en)	2022-04-26
AU2020270520B2 (en)	2023-01-05
JP2019178156A (ja)	2019-10-17
JP2024023367A (ja)	2024-02-21
PH12019502809A1 (en)	2021-07-26
IL276433B (en)	2021-05-31
PL3495367T3 (pl)	2021-04-19
DK3495367T3 (da)	2020-11-16
JP6301321B2 (ja)	2018-03-28
JP2018135377A (ja)	2018-08-30
HUE031916T2 (en)	2017-08-28
KR20200093696A (ko)	2020-08-05
PH12019502809B1 (en)	2024-04-24
MX2014015192A (es)	2015-08-07
PT2861595T (pt)	2017-04-03
TWI801156B (zh)	2023-05-01
MY171375A (en)	2019-10-10
US11840534B2 (en)	2023-12-12
JP2023027344A (ja)	2023-03-01
NO2021034I1 (no)	2021-09-09
CN104507943A (zh)	2015-04-08
JP7200170B2 (ja)	2023-01-06
US20130338134A1 (en)	2013-12-19
MX2022000517A (es)	2022-05-18
CY1118744T1 (el)	2017-07-12
PT3495367T (pt)	2020-11-12
EP3495367B1 (en)	2020-09-30
AU2013287176A1 (en)	2015-01-15
DK2861595T3 (en)	2017-02-13
ME02651B (me)	2017-06-20
KR20150036044A (ko)	2015-04-07
DK3176170T3 (en)	2019-01-28
AU2020270520A1 (en)	2020-12-17
CN107383009A (zh)	2017-11-24
SMT202000673T1 (it)	2021-01-05
US11053246B2 (en)	2021-07-06
LUC00222I2 (es)	2024-10-04
ES2984771T3 (es)	2024-10-31
EP3495367A1 (en)	2019-06-12
CY1121299T1 (el)	2020-05-29
NZ702747A (en)	2017-03-31
AR091424A1 (es)	2015-02-04
HUE052195T2 (hu)	2021-04-28
EP3822273A1 (en)	2021-05-19
SI3176170T1 (sl)	2019-05-31
CY2021026I1 (el)	2021-12-31
ECSP22091792A (es)	2023-01-31
CY1123631T1 (el)	2022-03-24
TWI706953B (zh)	2020-10-11
MX359293B (es)	2018-09-24
PL3176170T3 (pl)	2019-05-31
US10131667B2 (en)	2018-11-20
UA117347C2 (uk)	2018-07-25
LTPA2021519I1 (es)	2021-09-27
JP6336665B2 (ja)	2018-06-06
JP7392096B2 (ja)	2023-12-05
PE20150684A1 (es)	2015-05-11
ME03300B (me)	2019-07-20
IL256976B (en)	2020-08-31
HUE042374T2 (hu)	2019-06-28
CA3149881A1 (en)	2014-01-09
MX389376B (es)	2025-03-20
SG10201610416TA (en)	2017-01-27
LT3495367T (lt)	2021-02-25
TW202124382A (zh)	2021-07-01
KR20220080213A (ko)	2022-06-14
AU2013287176C1 (en)	2023-01-19
US20240246974A1 (en)	2024-07-25
PT3176170T (pt)	2019-02-05
LT2861595T (lt)	2017-02-27
IL256976A (en)	2018-03-29
IL282622B (en)	2022-02-01
US20210380587A1 (en)	2021-12-09
PH12014502772A1 (en)	2015-02-02
ES2618003T3 (es)	2017-06-20
US9611267B2 (en)	2017-04-04
JP2025084979A (ja)	2025-06-03
EP2861595B1 (en)	2016-12-21
IL282622A (en)	2021-06-30
IL289834B1 (en)	2024-03-01
HK1212326A1 (en)	2016-06-10
UA125503C2 (uk)	2022-04-13
AU2019200066B2 (en)	2020-08-27
US20170137424A1 (en)	2017-05-18
WO2014007951A2 (en)	2014-01-09
KR102406771B1 (ko)	2022-06-13
SMT201900040T1 (it)	2019-05-10
CA2876689A1 (en)	2014-01-09
RS55908B1 (sr)	2017-09-29
BR112014030812A2 (pt)	2017-07-25
WO2014007951A3 (en)	2014-03-06
JP2017222709A (ja)	2017-12-21
EP2861595B9 (en)	2017-06-21
CL2017001984A1 (es)	2018-03-23
AU2013287176B2 (en)	2018-10-04
EP4403216A3 (en)	2024-10-16
HUS2100035I1 (hu)	2021-10-28
US20200377504A1 (en)	2020-12-03
AU2022291504B2 (en)	2024-08-01
JP7646791B2 (ja)	2025-03-17
NL301131I1 (es)	2021-09-29
EP3176170A1 (en)	2017-06-07
CO7240375A2 (es)	2015-04-17
HRP20170430T1 (hr)	2017-06-16
IL236078B (en)	2019-08-29
IL289834B2 (en)	2024-07-01
EA036592B1 (ru)	2020-11-26
KR102140426B1 (ko)	2020-08-04
JP2015521600A (ja)	2015-07-30
SMT201700146T1 (it)	2017-05-08
SG11201408238WA (en)	2015-01-29
US20190127376A1 (en)	2019-05-02
JP2020143142A (ja)	2020-09-10
PE20190736A1 (es)	2019-05-23
IL289834A (en)	2022-03-01
EP4403216A2 (en)	2024-07-24
CN107383009B (zh)	2020-06-09

Publication	Publication Date	Title
CL2014003355A1 (es)	2015-06-12	Compuestos tricíclicos sustituidos, inhibidores del receptor del factor de crecimiento de fibroblastos (fgfr); composicion farmaceutica que los comprende; metodo para tratar cancer, trastorno mieloproliferativo, trastorno esqueletico, trastorno de hipofosfatemia, entre otros.
MX2017001031A (es)	2017-05-04	Móleculas de unión a her2 y cd3 biespecíficas.
CL2014001793A1 (es)	2014-11-07	Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
CL2014003227A1 (es)	2015-02-06	Compuestos derivados de imidazol condensados, como moduladores de la actividad del receptor del factor de crecimiento epidermico (egfr); composicion y combinacion farmaceutica que los comprende; y su uso para el tratamiento de cancer colorrectal, de mama, de pancreas, de ovario, entre otros.
CL2015000094A1 (es)	2015-06-19	Compuestos derivados de imidazotriazincarbonitrilos, inhibidores de la proteina cinasa; composicion farmaceutica que los comprende; y su uso para tratar el cancer, psoriasis y artritis reumatoide.
CL2015001733A1 (es)	2015-10-23	Compuestos derivados de lactamas fusionadas de arilo y heteroarilo, moduladores de ezh2; composicion farmaceutica que los comprende; uso del compuesto para el tratamiento del cancer.
CL2015000092A1 (es)	2015-08-07	Oligonucleótidos quiralmente controlados, composición que los comprende; método de elaboración: y uso para tratar cáncer.
GT201400297A (es)	2017-08-24	Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen
CL2015003280A1 (es)	2016-06-24	Derivados de benzimidazol como inhibidores de bromodominio
DOP2015000058A (es)	2015-04-15	Derivados tricíclicos de quinolinas y de quinoxalinas
CL2013001093A1 (es)	2013-09-27	Compuestos triciclicos inhibidores de la quinasa pi3 (pi3k); composicion farmaceutica que los comprende; metodo para tratar el cancer; y su uso para el tratamiento del cancer .
CR20150370A (es)	2015-08-14	Compuestos antivirales
MX377384B (es)	2025-03-10	Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cáncer.
UY35798A (es)	2015-05-29	Inhibidores del receptor del factor de crecimiento de fibroblastos
CL2015001437A1 (es)	2015-12-28	Derivados de pirimidin-2,4-diamina para el tratamiento de cancer
UY36076A (es)	2015-10-30	Compuestos útiles como inhibidores de la interacción proteínaproteína pd-1/pd-l1 y cd80/pd-l1, y composiciones farmacéuticas que los contienen.
UY35249A (es)	2014-07-31	Inhibidores del receptor del factor de crecimiento de fibroblastos
CL2015001377A1 (es)	2016-02-19	Inhbibidores de bmi-1 primidinas sustituidas inversas
CL2014003130A1 (es)	2015-04-24	Compuestos derivados de n-piridinil amidas ciclicas,inhibidores de quinasas pim; composicion farmaceutica que los comprende; combinacion farmaceutica; metodo para tratar enfermedades tales como canceres o un trastorno autoinmune.
UY35590A (es)	2014-11-28	Nuevos compuestos para el tratamiento del cáncer
CL2014001065A1 (es)	2014-07-25	Compuestos derivados de piridopirazinas; composicion farmaceutica que los comprende; y su uso para la prevencion o el tratamiento de un estado patologico o afeccion mediada por una fgfr cinasa tal como cancer.
CR20160501A (es)	2017-01-02	Derivados de quinoxalina útiles como amortiguadores del receptor del factor de crecimiento de fibroblastos (fgfr) cinasa
CL2015000256A1 (es)	2015-07-03	Compuestos heteroaromáticos, inhibidores de btk, composicion farmaceutica que los comprende y uso en enfermedades tales como artritis reumatoide, lupus, entre otras.
CL2012003110A1 (es)	2013-03-08	Compuestos derivados de n-[(2-oxo-1,2-dihidro-3-piridinil)metil]-1h-indol-4-carboxamida, inhibidores de ezh2; composicion farmaceutica que los contiene; utiles en el tratamiento del cancer seleccionado del grupo que consiste de cerebro (gliomas) glioblastomas, leucemias y linfomas, y trastornos mediados por la inhibicion del ezh2.
CL2014000566A1 (es)	2014-10-10	Compuestos derivados de pirrolopirimidina y purina, y sus sales farmaceuticamente aceptables; composicion farmaceutica que los comprende, util para el tratamiento del crecimiento celular anormal, tal como cancer.